stocks index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwall street isn’t ready for a point tumble in the dow industrials pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages phere’s one trump fan who might make you some money pwhy it might be time to invest in the companies amazon is destroying loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  tesaro inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report tesaro inc  product pipeline review   published by global markets direct product code  published march   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license tesaro inc  product pipeline review   published march   content info  pages description summary global markets directs tesaro inc  product pipeline review   provides an overview of the tesaro incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of tesaro incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of tesaro inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of tesaro incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the tesaro incs pipeline products reasons to buy evaluate tesaro incs strategic position with total access to detailed information on its product pipeline assess the growth potential of tesaro inc in its therapy areas of focus identify new drug targets and therapeutic classes in the tesaro incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of tesaro inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of tesaro inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of tesaro inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures tesaro inc snapshot tesaro inc overview key information key facts tesaro inc  research and development overview key therapeutic areas tesaro inc  pipeline review pipeline products by stage of development pipeline products  monotherapy tesaro inc  pipeline products glance tesaro inc  late stage pipeline products preregistration productscombination treatment modalities phase iii productscombination treatment modalities tesaro inc  clinical stage pipeline products phase i productscombination treatment modalities tesaro inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities tesaro inc  unknown stage pipeline products unknown productscombination treatment modalities tesaro inc  drug profiles rolapitant hydrochloride product description mechanism of action rd progress niraparib product description mechanism of action rd progress tsr product description mechanism of action rd progress monoclonal antibody to inhibit lag for cancer product description mechanism of action rd progress monoclonal antibody to inhibit tim for cancer product description mechanism of action rd progress tsr product description mechanism of action rd progress monoclonal antibody to inhibit pd and lag for cancer product description mechanism of action rd progress monoclonal antibody to inhibit pd and tim for cancer product description mechanism of action rd progress tesaro inc  pipeline analysis tesaro inc  pipeline products by target tesaro inc  pipeline products by route of administration tesaro inc  pipeline products by molecule type tesaro inc  pipeline products by mechanism of action tesaro inc  recent pipeline updates tesaro inc  dormant projects tesaro inc  company statement tesaro inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables tesaro inc key information tesaro inc key facts tesaro inc  pipeline by indication  tesaro inc  pipeline by stage of development  tesaro inc  monotherapy products in pipeline  tesaro inc  preregistration  tesaro inc  phase iii  tesaro inc  phase i  tesaro inc  preclinical  tesaro inc  discovery  tesaro inc  unknown  tesaro inc  pipeline by target  tesaro inc  pipeline by route of administration  tesaro inc  pipeline by molecule type  tesaro inc  pipeline products by mechanism of action  tesaro inc  recent pipeline updates  tesaro inc  dormant developmental projects list of figures tesaro inc  pipeline by top  indication  tesaro inc  pipeline by stage of development  tesaro inc  monotherapy products in pipeline  tesaro inc  pipeline by top  target  tesaro inc  pipeline by top  route of administration  tesaro inc  pipeline by top  molecule type  tesaro inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved stockscountryunited states index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwall street isn’t ready for a point tumble in the dow industrials pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages phere’s one trump fan who might make you some money pwhy it might be time to invest in the companies amazon is destroying loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  tesaro inc tsroo company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile tesaro inc tsroo related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse tsroo on nasdaq usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description tesaro inc incorporated on march   is an oncologyfocused biopharmaceutical company the company operates through the business of developing and commercializing of oncologyfocused therapeutics segment the company is developing oncologyrelated product candidates including rolapitant niraparib and the product candidates under its immunooncology platformrolapitantrolapitant is a potent and longacting neurokinin nk receptor antagonist for the prevention of chemotherapy induced nausea and vomiting cinv the oral form of rolapitant varubi is approved for commercialization in the united states and it is developing an intravenous iv formulation of rolapitant varubi is a substance pnk receptor antagonist marketed in oral formulation in the united states for use in combination with other antiemetic agents in adults for the prevention of delayed  to  hours after chemotherapy administration nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy including emetogenic chemotherapyniraparibniraparib is an orally active and potent poly adenosine diphosphate adpribose polymerase parp inhibitor the company has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers brca the company is also collaborating with various other organizations to evaluate niraparib in combination with other therapeutics for the treatment of various cancers the nova trial was a randomized doubleblind multicenter trial that assessed the effectiveness of niraparib compared with placebo to delay progression following a platinum containing chemotherapy regimen the bravo trial is a randomized multicenter trial that assesses the effectiveness of niraparib compared with physicians choice of either eribulin capecitabine vinorelbine or gemcitabine to delay progression in metastatic brca patients having germline brca mutations it has initiated dosing in a phase iii clinical trial of niraparib in the firstline maintenance setting in ovarian cancer patientsimmunooncology platformthe company in collaboration with anaptysbio inc anaptysbio has discovered and developed antibodies for various immunooncology targets the company has initiated a phase i dose escalation study for its first immunooncology antibody tsr which targets programmed cell death protein  pd it has commenced the dosing of the first patient in a phase i dose escalation study for its second immunooncology antibody tsr which targets tcell immunoglobulin domain and mucin domain tim it has commenced preclinical research for its antibody candidate targeting lymphocyteactivation gene lag and tsr it has commenced a phase i clinical trial of tsr in addition it is evaluating its immunooncology antitumor agents including tsr in preclinical combination studies with niraparib lag is a cluster of differentiation  cd related transmembrane protein expressed on activated tcells and regulatory tcellsthe company competes with merck  co inc helsinn healthcare sandoz astrazeneca plc clovis oncology inc pfizer abbvie eisai inc checkpoint therapeutics bristolmyers squibb roche novartis eli lilly jiangsu hengrui medicine co ltdincyte boehringer ingelheim beigene and regeneron pharmaceuticalssanofi » full overview of tsroo company address tesaro inc  winter st ste waltham   ma    p f  company web links home page officers  directors name compensation david mott  mary hedley  leon moulder  timothy pearson  jeffrey hanke  » more officers  directors tesaro inc news brieftesaro sale process seen unlikely to result in a deal  cnbc jul   cloviss ovarian cancer drug set for label expansion shares soar jun   update cloviss ovarian cancer drug set for label expansion shares soar jun   rptbrieftesaro inc is exploring a sale asked for initial bids  cnbc citing dj may   brieftesaro inc is exploring a sale asked for initial bids  cnbc may   » more tsroo news related topics stocksstock screenerhealthcarebiotechnology  medical research tsronasdaq gs stock quote  tesaro inc  bloomberg markets error could not add to watchlist x  watchlist tesaro inc tsrous nasdaq gs usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap b usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases  market recon worryingly the indices seem to be almost resting at lofty levels  the street  tesaro’s zejula flops as hs pattern emerges  investopedia  tesaro secures fda nod for ovarian cancer drug  investopedia  astrazeneca ovarian cancer drug succeeds in trial  investopedia  tesaro explores possible sale with investment bank  investopedia there are currently no news stories for this ticker please check back later  tesaro inc tesaro and takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy  tesaro and takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in japan  tesaro to announce secondquarter  financial results on august    tesaro joins ocrfa as presenting sponsor of the  ovarian cancer national conference  tesaro announces lonnie moulder and mary lynne hedley named ey entrepreneurs of the year® new england  tesaro joins healthcare businesswomen’s association as corporate partner  ewing sarcoma pipeline analysis by stage of development drug target and molecule type new report available at  tesaro announces participation at goldman sachs th annual global healthcare conference  tesaro provides business and pipeline update at asco investor briefing  veristat congratulates tesaro on the fda approval of zejula™ there are currently no press releases for this ticker please check back later profile tesaro inc develops and commercializes cancer therapeutics and supportive care products the company offers receptor antagonist for the prevention of chemotherapy induced nausea and vomiting tesaro operates in the united states address  winter streetsuite waltham ma united states phone  website wwwtesarobiocom executives board members leon o moulder lonnie ceocofounder mary lynne hedley prescoocofounder timothy r pearson tim exec vpcfo jeffrey h hanke exec vpresearchchief scientific ofcr grant c bogle senior vpchief commercial ofcr show more tsro  stock quote for tesaro inc  msn money msn back to msn home money web search sign in change language  content américa latina español argentina español australia english belgië nederlands belgique français brasil português canada english canada français chile español colombia español danmark dansk deutschland deutsch españa español france français india english indonesia bahasa indonesia ireland english italia italiano malaysia english méxico español nederland nederlands new zealand english norge norsk bokmål österreich deutsch perú español philippines english polska polski portugal português schweiz deutsch singapore english south africa english suisse français suomi suomi sverige svenska türkiye türkçe united arab emirates english united kingdom english united states english united states español venezuela español việt nam tiếng việt ελλάδα ελληνικά россия pусский ישראל עברית‏ الإمارات العربية المتحدة العربية‏ المملكة العربية السعودية العربية‏ مصر العربية‏ ไทย ไทย 한국 한국어      語   switch to latino español feedback help adchoices tesaro inc nasdaq tsro us markets closed adchoices  ▲   after hours     july    pm edt delayed  minutes nasdaq currency in usd save summary financials analysis options ownership company history related open  previous close  volume avg k m days range  wk range  market cap b dividend rate  yield  beta  shares outstanding m pe ratio eps  recent news juno therapeutics juno q earnings surprise in store zacks equity research tesaros stock dip is nothing to be afraid of seeking alpha why national beverage tesaro and community health systems slumped today the motley fool midafternoon market update crude oil up  dragonwave shares plunge benzinga tesaro inc tsro shares fall as company struggles to find buyer investorplace midday market update yandex jumps following announcement of deal with uber amicus therapeutics shares drop benzinga sale process for biotech tesaro seen unlikely to result in deal cnbc tesla earnings preview with options ideas zacks equity research key fda events to watch out for in jul  zacks equity research is it too late to buy clovis oncology stock the motley fool how things look for opko health inc in  charts the motley fool  reasons why biotech etfs are soaring zacks equity research  stocks  etfs to buy on clovis positive drug data zacks equity research clovis up nearly  on solid data from ovarian cancer study zacks equity research clovis oncologys rubraca notches key trial win the motley fool why tesaro inc stock briefly dipped today the motley fool why clovis oncology stock is soaring today the motley fool  stocks moving in mondays premarket session benzinga  biotech stocks that could become ma targets the motley fool will tesaro be the focus of the next biotech bidding war the motley fool notes from asco  tesaro amgen others report new data benzinga key fda events to watch out for in jun  zacks equity research biotech forum daily digest will tesaro get bids spotlight on zogenix seeking alpha adchoices adchoices adchoices markets dow dow ▲    last updated time   pm edt markets nasdaq nasdaq ▼    ftse  ftse  ▼    nyse composite nyse composite ▼    adchoices feedback send feedback provide feedback report a problem we appreciate your input select a category im having problems with top destinations im having issues searching im having problems with featured apps i see an error in the content other how we can improve please give an overall site rating submit close privacy statement help help  support tesaro inc  investor relations   together we can make a difference investor relations we are committed to serving the best interests of our shareholders print email share facebook google linkedin twitter email rss stock quote tsro      pm et on  previous close  open  volume  exchange nasdaq day high  day low  week high  week low   mo  mo  yr press releases  tesaro and takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in japan  tesaro to announce secondquarter  financial results on august   view all press releases investors press releases events  presentations corporate governance sec filings stock information faq investor contact press kit shareholder tools briefcase email alerts snapshot rss facebook google linkedin twitter email rss search investor relations stocks index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwall street isn’t ready for a point tumble in the dow industrials pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages phere’s one trump fan who might make you some money pwhy it might be time to invest in the companies amazon is destroying loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  tsro stock price  tesaro inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers algn  mhk  col  lyb  fls  mo  sbux  gt  latest newsall times eastern p updated wall street isn’t ready for a point tumble in the dow industrials p updated the dark side of cruises p trump to police dont be too nice p updated the highest paid athletes in the world in one chart p updated oj simpson made over  while in prison and won’t have to give any of it to the goldman family p updated here are  coworkers you should avoid like the plague — especially in meetings p updated top  most annoying people you may want to unfriend on facebook p updated this is one person you should never unfriend on facebook p updated  horrible ways typos could alter the course of your life p updated paint your bathroom this color and boost your home’s selling price by  to be replaced home investing quotes stocks united states tsro overview compare quotes stock screener earnings calendar sectors nasdaq tsro us nasdaq join td ameritrade find a broker tesaro inc watchlist createtsroalert after hours last updated jul    pm edt delayed quote     after hours volume k close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  m open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap b shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume m performance  day   month   month  ytd   year  recent news marketwatch other dow jones clovis oncology stock surges  on positive latestage cancer trial results clovis oncology inc shares surged  in premarket trade monday after the company said its latestage trial for a cancer drug met its primary endpoint and a key secondary endpoint clovis said it plans to try for food and drug administration approval for the drug rucaparib within the next four months for second line and later maintenance treatment for women with platinumsensitive ovarian cancer who have responded to their most recent platinum therapy leerink analyst michael schmidt described the latest results as bull case plays out the outcome looks to be the bestcasescenario for clvs he said adding the results look particularly impressive when compared to previous competitor data including companies like tesaro and astrazeneca  which are also developing a class of cancer drugs called parp inhibitors if approved rubraca would have the broadest label of any parp inhibitor in ovarian cancer which we think should bode well for the commercial uptake of the drug schmidt said calling the company a prime takeout candidate in three subgroups of women with ovarian fallopian tube or primary peritoneal cancer patients on rucaparib had improved progressionfree survival the phase  trials primary endpoint progressionfree survival was also improved in patient on the drug as compared with placebo a key secondary endpoint clovis oncology said the trial enrolled  women clovis oncology shares have dropped  to  over the last three months compared with a  rise in the sp   jun   at  am et by emma court tesaro stock dips  on ‘probably a nothing burger’ jun   at  pm et by emma court tesaro stock price target raised to  from  at oppenheimer tesaro stock price target raised to  from  at oppenheimer jun   at  am et by tomi kilgore drug maker tesaro looks for buyer wsj drug maker tesaro inc is exploring a sale the wall street journal reported wednesday citing people familiar with the matter the company which two months ago won a key approval for its ovarian cancer drug has asked for offers in recent weeks but interest has been tepid and no deal might be forthcoming according to the report tesaro shares rallied on the news and closed  higher may   at  pm et by claudia assis shares of tesaro jump  in lateafternoon trade on report it is exploring a sale shares of tesaro jump  in lateafternoon trade on report it is exploring a sale may   at  pm et by mark decambre neurocrine biosciences’ new drug may cost patients more than  a month twice as much as expected may   at  am et by emma court tesaro stock dives  after drug pricing snafu apr   at  am et by emma court these corporate ties will be on display at scott gottlieb’s fda commissioner confirmation hearing today apr   at  am et by emma court tesaro won’t reveal price of its ovarian cancer drug but it’ll likely be near  a month mar   at  am et by emma court tesaro stock price target raised to  from  at wedbush securities mar   at  am et by tomi kilgore tesaro stock rises  on news that its ovarian cancer drug was approved by the fda mar   at  pm et by emma court tesaro says its ovarian cancer drug has been approved by the fda mar   at  pm et by emma court tesaro stock halted on news that its latestage ovarian cancer drug will be developed for other cancers mar   at  pm et by emma court tesaros stock was down  prior to trading halt mar   at  pm et by tomi kilgore tesaro stock halted for news pending mar   at  pm et by tomi kilgore tesaro stock price target raised to  from  at fbr  co feb   at  am et by tomi kilgore tesaro downgraded to market perform from outperform at fbr  co feb   at  am et by tomi kilgore tesaro downgraded to market perform at leerink feb   at  am et by caitlin huston opinion we’re in the year of the biotech buyout and here are five prime targets jan   at  pm et by michael brush tesaro stock price target raised to  from  at leerink partners jan   at  am et by tomi kilgore the dark side of good news in biotech deal making is a staple of the biotech industry but betting on mergers and acquisitions is much harder than it looks for investors jun   at  am et on the wall street journal tesaro explores sale tesaro is exploring a sale according to people familiar with the matter two months after the cancertreatment developer won a key drug approval may   at  pm et on the wall street journal four biotech picks ahead of earnings apr   at  pm et on barrons the magic shrinking drug price apr   at  am et on the wall street journal your cancer drugs may soon be discovered in china apr   at  am et on the wall street journal and the no  stockfund manager this time is…shhhh apr   at  pm et on the wall street journal beatendown biotechs may be worth buying apr   at  pm et on barrons biotech ma trade hits a snag mar   at  am et on the wall street journal the time is right for convertible bonds jan   at  am et on barrons stocks to watch delta air lines tesaro apple jan   at  am et on the wall street journal active stockpickers are outpacing passive funds nov   at  am et on barrons the next big moves in healthcare stocks oct   at  am et on barrons big pharma not small investors is driving biotech values now sep   at  pm et on the wall street journal would gilead pick up tesaro’s parp sep   at  pm et on barrons new drugs for ovarian cancer patients sep   at  am et on the wall street journal smaller biotech buyout targets after medivation aug   at  am et on barrons tesaro’s cancer drug meets primary endpoint in latestage trial jun   at  am et on the wall street journal what does brexit say about the health of us financial system jun   at  am et on the wall street journal myriad genetics’ upside slips may   at  am et on barrons johnson  johnson to develop tesaro’s drug for prostate cancer apr   at  am et on the wall street journal recent news other news press releases juno therapeutics juno q earnings surprise in store although juno therapeutics juno product portfolio shows a dearth of any revenue figures the companys most advanced pipeline candidates  jcar and jcar  might drive its progress in q jul   at  pm et on zackscom how astrazeneca failed not once — but twice — in cancer drugs astrazeneca azn not only failed in a lung cancer trial — which had the side effect of sending rival bristolmyers squibb bmy spiraling — but its partnership with dows merck mrk appears to be an admission of defeat in the initial immunooncology race shares of astrazeneca and bristolmyers sold off in droves early thursday on the stock market today astrazeneca took a pitfall to a fivemonth low down  near  bristol too jul   at  pm et on investors business daily tesaro outlicenses niraparib to takeda for up to m tesaro outlicenses niraparib to takeda for up to m jul   at  am et on seeking alpha whats in store for agios pharma agio in q earnings encouraging performance of agios agio lead candidate idhifa which is under review in the us for treatment of aml might drive the stock in q jul   at  am et on zackscom whats in store for conatus cnat this earnings season conatus cnat aim to progress with its lead candidate emricasan might boost the stock in q results although the companys current portfolio shows no approved product and revenue generation jul   at  am et on zackscom biotech bonanza the next leg up biotech bonanza the next leg up jul   at  pm et on seeking alpha tesaros stock dip is nothing to be afraid of tesaros stock dip is nothing to be afraid of jul   at  pm et on seeking alpha fdas flashing green light boosts novel drug approvals fdas flashing green light boosts novel drug approvals jul   at  pm et on seeking alpha  assets with negative performances  assets with negative performances jul   at  pm et on gurufocuscom gilead could acquire this biotech — but vertex is still better analyst gilead sciences gild could fill a hole in its portfolio by acquiring incyte incy an analyst suggested friday offering one caveat — vertex pharmaceuticals vrtx would still be a less risky bet though gilead could make a play now for incyte — to the tune of a  premium on its stock price — the no  biotech would largely be betting on the commercial success of incytes immunooncology drug epacadostat meanwhile its dealing with a jul   at  pm et on investors business daily could q surprise spike this beleaguered biotechs stock a key hepatitis c drug from gilead sciences gild could top wall streets expectations but investors will be tuning into the companys secondquarter report on july  for more hints on potential ma activity an analyst said friday gileads hepatitis c sales slipped in  and in the months following the no  biotech said it could be open to a deal especially in oncology analysts have been quick to offer up incyte incy tesaro tsro jul   at  pm et on investors business daily clovis clvs focuses on rubraca launch and label expansion we issued an updated research report on boulder cobased clovis oncology inc clvs on jul  jul   at  pm et on zackscom why national beverage tesaro and community health systems slumped today jul   at  pm et on motley fool tesaro inc tsro shares fall as company struggles to find buyer tesaro inc tsro shares fall as company struggles to find buyer jul   at  pm et on investorplacecom tesaro down  on diminished prospects for deal tesaro down  on diminished prospects for deal jul   at  am et on seeking alpha tesaro shows good potential with major approvals this year tesaro shows good potential with major approvals this year jul   at  pm et on seeking alpha is the options market predicting a spike in tesaro inc tsro stock options market is predicting a spike in tesaro inc tsro stock on the back of its surging implied volatility jul   at  am et on zackscom are gileads fortunes about to change — without an acquisition gilead sciences gild fortunes are likely to change this summer on the expected approval of a key hepatitis c drug regimen and after the no  biotech unveils phase  data from an hiv trial an analyst said friday year to date gilead stock is down  as of thursdays close shares declined as much as  to the years low of  on june  but have since recovered somewhat amid a biotech rally that saw the sector rise collectively to a jul   at  pm et on investors business daily gilead and vertex should join — but dont hold your breath analyst gilead sciences gild would be better off acquiring vertex pharmaceuticals vrtx than an oncology asset like tesaro tsro or incyte incy an analyst suggested friday as he lamented gileads cautious approach to mergers the no  biotech by market cap has shown interest in making an oncologycentric buy as it struggles with declining hepatitis c drug sales the hepatitis c franchise brought in north of  billion over three years but fell jun   at  pm et on investors business daily opko health poised for growth opko health poised for growth jun   at  am et on seeking alpha tesaro and takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in japan tesaro and takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in japan jul   at  am et on globe newswire tesaro to announce secondquarter  financial results on august   tesaro to announce secondquarter  financial results on august   jul   at  pm et on globenewswire sta signs supply agreement with tesaro sta signs supply agreement with tesaro jul   at  pm et on pr newswire  prf stocks under scanner in the biotech space  achillion pharma kite pharma acorda therapeutics and tesaro stocks under scanner in the biotech space  achillion pharma kite pharma acorda therapeutics and tesaro jul   at  am et on pr newswire  prf tesaro joins ocrfa as presenting sponsor of the  ovarian cancer national conference tesaro joins ocrfa as presenting sponsor of the  ovarian cancer national conference jun   at  am et on globenewswire tesaro announces lonnie moulder and mary lynne hedley named ey entrepreneurs of the yearr new england tesaro announces lonnie moulder and mary lynne hedley named ey entrepreneurs of the yearr new england jun   at  am et on globenewswire tesaro joins healthcare businesswomens association as corporate partner tesaro joins healthcare businesswomens association as corporate partner jun   at  pm et on globenewswire todays research reports on stocks to watch gilead sciences and tesaro todays research reports on stocks to watch gilead sciences and tesaro jun   at  am et on accesswire tesaro announces participation at goldman sachs th annual global healthcare conference tesaro announces participation at goldman sachs th annual global healthcare conference jun   at  pm et on globenewswire corporate news blog  puma biotech announced positive results from pb phaseii data at the asco  corporate news blog  puma biotech announced positive results from pb phaseii data at the asco  jun   at  am et on accesswire national survey shows resource emotional and support needs of the ovarian cancer community national survey shows resource emotional and support needs of the ovarian cancer community may   at  am et on globenewswire tesaro partners with clinigen to initiate european managed access program for niraparib in patients with recurrent ovarian cancer tesaro partners with clinigen to initiate european managed access program for niraparib in patients with recurrent ovarian cancer may   at  am et on globenewswire investor network tesaro inc to host earnings call investor network tesaro inc to host earnings call may   at  am et on accesswire tesaro announces submission of investigational new drug application for antilag antibody tsr to the us fda tesaro announces submission of investigational new drug application for antilag antibody tsr to the us fda may   at  am et on globenewswire tesaro initiates registrational development program for antipd antibody tsr apr   at  am et on globenewswire tesaro announces approval of varubyr oral rolapitant tablets by european commission apr   at  am et on globe newswire tesaro announces approval of varubyr oral rolapitant tablets by european commission apr   at  am et on globenewswire tesaro to announce firstquarter  financial results on may   apr   at  pm et on globenewswire tesaro announces participation in two investor conferences apr   at  pm et on globenewswire biologics inc selected by tesaro as a specialty pharmacy provider for zejulatm niraparib approved for the treatment of recurrent ovarian cancer apr   at  pm et on businesswire  bzx tesaro inc tesaro inc engages in the research and development of biopharmaceutical products it focuses on oncologybased therapeutics and consists of the following portfolio rolapitant iv and niraparib the company was founded by leon moulder jr mary lynne hedley and richard j rodgers on march   and is headquartered in waltham ma see full profile analyst ratings sell under hold over buy number of ratings  full ratings notes from asco  tesaro amgen others report new data jun   at  pm et on benzingacom fast money picks for june  jun   at  am et on benzingacom the current state of the breast cancer treatment space may   at  am et on benzingacom competitors name chg  market cap amgen inc  b ziopharm oncology inc  m bristolmyers squibb co  b pfizer inc  b merck  co inc  b competitor data provided by partner content trending tickers powered by dvax  mo  ssti  clvs  icpt  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience tsro stock price  tesaro inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers algn  mhk  col  lyb  fls  mo  sbux  gt  latest newsall times eastern p updated wall street isn’t ready for a point tumble in the dow industrials p updated the dark side of cruises p trump to police dont be too nice p updated the highest paid athletes in the world in one chart p updated oj simpson made over  while in prison and won’t have to give any of it to the goldman family p updated here are  coworkers you should avoid like the plague — especially in meetings p updated top  most annoying people you may want to unfriend on facebook p updated this is one person you should never unfriend on facebook p updated  horrible ways typos could alter the course of your life p updated paint your bathroom this color and boost your home’s selling price by  to be replaced home investing quotes stocks united states tsro overview compare quotes stock screener earnings calendar sectors nasdaq tsro us nasdaq join td ameritrade find a broker tesaro inc watchlist createtsroalert after hours last updated jul    pm edt delayed quote     after hours volume k close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  m open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap b shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume m performance  day   month   month  ytd   year  recent news marketwatch other dow jones clovis oncology stock surges  on positive latestage cancer trial results clovis oncology inc shares surged  in premarket trade monday after the company said its latestage trial for a cancer drug met its primary endpoint and a key secondary endpoint clovis said it plans to try for food and drug administration approval for the drug rucaparib within the next four months for second line and later maintenance treatment for women with platinumsensitive ovarian cancer who have responded to their most recent platinum therapy leerink analyst michael schmidt described the latest results as bull case plays out the outcome looks to be the bestcasescenario for clvs he said adding the results look particularly impressive when compared to previous competitor data including companies like tesaro and astrazeneca  which are also developing a class of cancer drugs called parp inhibitors if approved rubraca would have the broadest label of any parp inhibitor in ovarian cancer which we think should bode well for the commercial uptake of the drug schmidt said calling the company a prime takeout candidate in three subgroups of women with ovarian fallopian tube or primary peritoneal cancer patients on rucaparib had improved progressionfree survival the phase  trials primary endpoint progressionfree survival was also improved in patient on the drug as compared with placebo a key secondary endpoint clovis oncology said the trial enrolled  women clovis oncology shares have dropped  to  over the last three months compared with a  rise in the sp   jun   at  am et by emma court tesaro stock dips  on ‘probably a nothing burger’ jun   at  pm et by emma court tesaro stock price target raised to  from  at oppenheimer tesaro stock price target raised to  from  at oppenheimer jun   at  am et by tomi kilgore drug maker tesaro looks for buyer wsj drug maker tesaro inc is exploring a sale the wall street journal reported wednesday citing people familiar with the matter the company which two months ago won a key approval for its ovarian cancer drug has asked for offers in recent weeks but interest has been tepid and no deal might be forthcoming according to the report tesaro shares rallied on the news and closed  higher may   at  pm et by claudia assis shares of tesaro jump  in lateafternoon trade on report it is exploring a sale shares of tesaro jump  in lateafternoon trade on report it is exploring a sale may   at  pm et by mark decambre neurocrine biosciences’ new drug may cost patients more than  a month twice as much as expected may   at  am et by emma court tesaro stock dives  after drug pricing snafu apr   at  am et by emma court these corporate ties will be on display at scott gottlieb’s fda commissioner confirmation hearing today apr   at  am et by emma court tesaro won’t reveal price of its ovarian cancer drug but it’ll likely be near  a month mar   at  am et by emma court tesaro stock price target raised to  from  at wedbush securities mar   at  am et by tomi kilgore tesaro stock rises  on news that its ovarian cancer drug was approved by the fda mar   at  pm et by emma court tesaro says its ovarian cancer drug has been approved by the fda mar   at  pm et by emma court tesaro stock halted on news that its latestage ovarian cancer drug will be developed for other cancers mar   at  pm et by emma court tesaros stock was down  prior to trading halt mar   at  pm et by tomi kilgore tesaro stock halted for news pending mar   at  pm et by tomi kilgore tesaro stock price target raised to  from  at fbr  co feb   at  am et by tomi kilgore tesaro downgraded to market perform from outperform at fbr  co feb   at  am et by tomi kilgore tesaro downgraded to market perform at leerink feb   at  am et by caitlin huston opinion we’re in the year of the biotech buyout and here are five prime targets jan   at  pm et by michael brush tesaro stock price target raised to  from  at leerink partners jan   at  am et by tomi kilgore the dark side of good news in biotech deal making is a staple of the biotech industry but betting on mergers and acquisitions is much harder than it looks for investors jun   at  am et on the wall street journal tesaro explores sale tesaro is exploring a sale according to people familiar with the matter two months after the cancertreatment developer won a key drug approval may   at  pm et on the wall street journal four biotech picks ahead of earnings apr   at  pm et on barrons the magic shrinking drug price apr   at  am et on the wall street journal your cancer drugs may soon be discovered in china apr   at  am et on the wall street journal and the no  stockfund manager this time is…shhhh apr   at  pm et on the wall street journal beatendown biotechs may be worth buying apr   at  pm et on barrons biotech ma trade hits a snag mar   at  am et on the wall street journal the time is right for convertible bonds jan   at  am et on barrons stocks to watch delta air lines tesaro apple jan   at  am et on the wall street journal active stockpickers are outpacing passive funds nov   at  am et on barrons the next big moves in healthcare stocks oct   at  am et on barrons big pharma not small investors is driving biotech values now sep   at  pm et on the wall street journal would gilead pick up tesaro’s parp sep   at  pm et on barrons new drugs for ovarian cancer patients sep   at  am et on the wall street journal smaller biotech buyout targets after medivation aug   at  am et on barrons tesaro’s cancer drug meets primary endpoint in latestage trial jun   at  am et on the wall street journal what does brexit say about the health of us financial system jun   at  am et on the wall street journal myriad genetics’ upside slips may   at  am et on barrons johnson  johnson to develop tesaro’s drug for prostate cancer apr   at  am et on the wall street journal recent news other news press releases juno therapeutics juno q earnings surprise in store although juno therapeutics juno product portfolio shows a dearth of any revenue figures the companys most advanced pipeline candidates  jcar and jcar  might drive its progress in q jul   at  pm et on zackscom how astrazeneca failed not once — but twice — in cancer drugs astrazeneca azn not only failed in a lung cancer trial — which had the side effect of sending rival bristolmyers squibb bmy spiraling — but its partnership with dows merck mrk appears to be an admission of defeat in the initial immunooncology race shares of astrazeneca and bristolmyers sold off in droves early thursday on the stock market today astrazeneca took a pitfall to a fivemonth low down  near  bristol too jul   at  pm et on investors business daily tesaro outlicenses niraparib to takeda for up to m tesaro outlicenses niraparib to takeda for up to m jul   at  am et on seeking alpha whats in store for agios pharma agio in q earnings encouraging performance of agios agio lead candidate idhifa which is under review in the us for treatment of aml might drive the stock in q jul   at  am et on zackscom whats in store for conatus cnat this earnings season conatus cnat aim to progress with its lead candidate emricasan might boost the stock in q results although the companys current portfolio shows no approved product and revenue generation jul   at  am et on zackscom biotech bonanza the next leg up biotech bonanza the next leg up jul   at  pm et on seeking alpha tesaros stock dip is nothing to be afraid of tesaros stock dip is nothing to be afraid of jul   at  pm et on seeking alpha fdas flashing green light boosts novel drug approvals fdas flashing green light boosts novel drug approvals jul   at  pm et on seeking alpha  assets with negative performances  assets with negative performances jul   at  pm et on gurufocuscom gilead could acquire this biotech — but vertex is still better analyst gilead sciences gild could fill a hole in its portfolio by acquiring incyte incy an analyst suggested friday offering one caveat — vertex pharmaceuticals vrtx would still be a less risky bet though gilead could make a play now for incyte — to the tune of a  premium on its stock price — the no  biotech would largely be betting on the commercial success of incytes immunooncology drug epacadostat meanwhile its dealing with a jul   at  pm et on investors business daily could q surprise spike this beleaguered biotechs stock a key hepatitis c drug from gilead sciences gild could top wall streets expectations but investors will be tuning into the companys secondquarter report on july  for more hints on potential ma activity an analyst said friday gileads hepatitis c sales slipped in  and in the months following the no  biotech said it could be open to a deal especially in oncology analysts have been quick to offer up incyte incy tesaro tsro jul   at  pm et on investors business daily clovis clvs focuses on rubraca launch and label expansion we issued an updated research report on boulder cobased clovis oncology inc clvs on jul  jul   at  pm et on zackscom why national beverage tesaro and community health systems slumped today jul   at  pm et on motley fool tesaro inc tsro shares fall as company struggles to find buyer tesaro inc tsro shares fall as company struggles to find buyer jul   at  pm et on investorplacecom tesaro down  on diminished prospects for deal tesaro down  on diminished prospects for deal jul   at  am et on seeking alpha tesaro shows good potential with major approvals this year tesaro shows good potential with major approvals this year jul   at  pm et on seeking alpha is the options market predicting a spike in tesaro inc tsro stock options market is predicting a spike in tesaro inc tsro stock on the back of its surging implied volatility jul   at  am et on zackscom are gileads fortunes about to change — without an acquisition gilead sciences gild fortunes are likely to change this summer on the expected approval of a key hepatitis c drug regimen and after the no  biotech unveils phase  data from an hiv trial an analyst said friday year to date gilead stock is down  as of thursdays close shares declined as much as  to the years low of  on june  but have since recovered somewhat amid a biotech rally that saw the sector rise collectively to a jul   at  pm et on investors business daily gilead and vertex should join — but dont hold your breath analyst gilead sciences gild would be better off acquiring vertex pharmaceuticals vrtx than an oncology asset like tesaro tsro or incyte incy an analyst suggested friday as he lamented gileads cautious approach to mergers the no  biotech by market cap has shown interest in making an oncologycentric buy as it struggles with declining hepatitis c drug sales the hepatitis c franchise brought in north of  billion over three years but fell jun   at  pm et on investors business daily opko health poised for growth opko health poised for growth jun   at  am et on seeking alpha tesaro and takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in japan tesaro and takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in japan jul   at  am et on globe newswire tesaro to announce secondquarter  financial results on august   tesaro to announce secondquarter  financial results on august   jul   at  pm et on globenewswire sta signs supply agreement with tesaro sta signs supply agreement with tesaro jul   at  pm et on pr newswire  prf stocks under scanner in the biotech space  achillion pharma kite pharma acorda therapeutics and tesaro stocks under scanner in the biotech space  achillion pharma kite pharma acorda therapeutics and tesaro jul   at  am et on pr newswire  prf tesaro joins ocrfa as presenting sponsor of the  ovarian cancer national conference tesaro joins ocrfa as presenting sponsor of the  ovarian cancer national conference jun   at  am et on globenewswire tesaro announces lonnie moulder and mary lynne hedley named ey entrepreneurs of the yearr new england tesaro announces lonnie moulder and mary lynne hedley named ey entrepreneurs of the yearr new england jun   at  am et on globenewswire tesaro joins healthcare businesswomens association as corporate partner tesaro joins healthcare businesswomens association as corporate partner jun   at  pm et on globenewswire todays research reports on stocks to watch gilead sciences and tesaro todays research reports on stocks to watch gilead sciences and tesaro jun   at  am et on accesswire tesaro announces participation at goldman sachs th annual global healthcare conference tesaro announces participation at goldman sachs th annual global healthcare conference jun   at  pm et on globenewswire corporate news blog  puma biotech announced positive results from pb phaseii data at the asco  corporate news blog  puma biotech announced positive results from pb phaseii data at the asco  jun   at  am et on accesswire national survey shows resource emotional and support needs of the ovarian cancer community national survey shows resource emotional and support needs of the ovarian cancer community may   at  am et on globenewswire tesaro partners with clinigen to initiate european managed access program for niraparib in patients with recurrent ovarian cancer tesaro partners with clinigen to initiate european managed access program for niraparib in patients with recurrent ovarian cancer may   at  am et on globenewswire investor network tesaro inc to host earnings call investor network tesaro inc to host earnings call may   at  am et on accesswire tesaro announces submission of investigational new drug application for antilag antibody tsr to the us fda tesaro announces submission of investigational new drug application for antilag antibody tsr to the us fda may   at  am et on globenewswire tesaro initiates registrational development program for antipd antibody tsr apr   at  am et on globenewswire tesaro announces approval of varubyr oral rolapitant tablets by european commission apr   at  am et on globe newswire tesaro announces approval of varubyr oral rolapitant tablets by european commission apr   at  am et on globenewswire tesaro to announce firstquarter  financial results on may   apr   at  pm et on globenewswire tesaro announces participation in two investor conferences apr   at  pm et on globenewswire biologics inc selected by tesaro as a specialty pharmacy provider for zejulatm niraparib approved for the treatment of recurrent ovarian cancer apr   at  pm et on businesswire  bzx tesaro inc tesaro inc engages in the research and development of biopharmaceutical products it focuses on oncologybased therapeutics and consists of the following portfolio rolapitant iv and niraparib the company was founded by leon moulder jr mary lynne hedley and richard j rodgers on march   and is headquartered in waltham ma see full profile analyst ratings sell under hold over buy number of ratings  full ratings notes from asco  tesaro amgen others report new data jun   at  pm et on benzingacom fast money picks for june  jun   at  am et on benzingacom the current state of the breast cancer treatment space may   at  am et on benzingacom competitors name chg  market cap amgen inc  b ziopharm oncology inc  m bristolmyers squibb co  b pfizer inc  b merck  co inc  b competitor data provided by partner content trending tickers powered by dvax  mo  ssti  clvs  icpt  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience tesaro inc  investor contact   together we can make a difference investor contact we are committed to serving the best interests of our shareholders print email share facebook google linkedin twitter email rss please submit your question using the form below contact form  indicates required field name email subject comments listen to audio version type in number submit comment investors press releases events  presentations corporate governance sec filings stock information faq investor contact press kit shareholder tools briefcase email alerts snapshot rss facebook google linkedin twitter email rss search investor relations microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft tsro key statistics  tesaro inc financial ratios  marketwatch bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close tesaro inc nasdaq tsro go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus tesaro inc after hours  quotes are delayed by  min jul    pm tsro quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   company description tesaro inc engages in the research and development of biopharmaceutical products it focuses on oncologybased therapeutics and consists of the following portfolio rolapitant iv and niraparib the company was founded by leon moulder jr mary lynne hedley and richard j rodgers on march   tesaro inc engages in the research and development of biopharmaceutical products it focuses on oncologybased therapeutics and consists of the following portfolio rolapitant iv and niraparib the company was founded by leon moulder jr mary lynne hedley and richard j rodgers on march   and is headquartered in waltham ma valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  longterm debt to equity  longterm debt to total capital  officers and executives name age officer since title mr leon o moulder   chief executive officer  director dr mary lynne hedley   president chief operating officer  director mr timothy r pearson   chief financial officer  executive vice president dr jeffrey h hanke   chief scientific officer dr martin h huber   chief medical officer  senior vice president insider actions – purchase – sale  – number of transactions  date name shares transaction value  edward c english vp of finance  administration    disposition at  per share   edward c english vp of finance  administration    disposition at  per share   edward c english vp of finance  administration    disposition at  per share   edward c english vp of finance  administration    disposition at  per share   edward c english vp of finance  administration    derivativenonderivative trans at  per share   edward c english vp of finance  administration    derivativenonderivative trans at  per share   interwest partners llc director    award at  per share   lawrence m alleva director    award at  per share   garry a nicholson director    award at  per share   kavita patel director    award at  per share   earl m collier director    award at  per share   martin h huber svp  cheif medical officer    disposition at  per share   martin h huber svp  cheif medical officer    derivativenonderivative trans at  per share   edward c english vp of finance  administration    disposition at  per share   edward c english vp of finance  administration    derivativenonderivative trans at  per share   edward c english vp of finance  administration    derivativenonderivative trans at  per share   mary lynne hedley president  coo director    disposition at  per share   martin h huber svp  cheif medical officer    disposition at  per share   orlando oliveira svp  gm international    disposition at  per share   joseph l farmer sr vpgen counsel  secretary    disposition at  per share   grant c bogle sr vpchief commercial officer    disposition at  per share   timothy r pearson exec vp cfo    disposition at  per share   edward c english vp of finance  administration    disposition at  per share   leon o moulder chief executive officer director    derivativenonderivative trans at  per share   mary lynne hedley president  coo director    derivativenonderivative trans at  per share   martin h huber svp  cheif medical officer    derivativenonderivative trans at  per share   orlando oliveira svp  gm international    derivativenonderivative trans at  per share   joseph l farmer sr vpgen counsel  secretary    derivativenonderivative trans at  per share   grant c bogle sr vpchief commercial officer    derivativenonderivative trans at  per share   timothy r pearson exec vp cfo    derivativenonderivative trans at  per share   edward c english vp of finance  administration    derivativenonderivative trans at  per share   martin h huber svp  cheif medical officer    disposition at  per share   martin h huber svp  cheif medical officer    award at  per share   edward c english vp of finance  administration    disposition at  per share   edward c english vp of finance  administration    disposition at  per share   edward c english vp of finance  administration    derivativenonderivative trans at  per share   edward c english vp of finance  administration    derivativenonderivative trans at  per share  newslatestcompanyustsro marketwatch news on tsro clovis oncology stock surges  on positive latestage cancer trial results  am june    emma court tesaro stock dips  on ‘probably a nothing burger’  pm june    emma court tesaro stock price target raised to  from  at oppenheimer  am june    tomi kilgore drug maker tesaro looks for buyer wsj  pm may    claudia assis shares of tesaro jump  in lateafternoon trade on report it is exploring a sale  pm may    mark decambre neurocrine biosciences’ new drug may cost patients more than  a month twice as much as expected  am may    emma court tesaro stock dives  after drug pricing snafu  am april    emma court these corporate ties will be on display at scott gottlieb’s fda commissioner confirmation hearing today  am april    emma court tesaro won’t reveal price of its ovarian cancer drug but it’ll likely be near  a month  am march    emma court tesaro stock price target raised to  from  at wedbush securities  am march    tomi kilgore tesaro stock rises  on news that its ovarian cancer drug was approved by the fda  pm march    emma court tesaro says its ovarian cancer drug has been approved by the fda  pm march    emma court tesaro stock halted on news that its latestage ovarian cancer drug will be developed for other cancers  pm march    emma court tesaros stock was down  prior to trading halt  pm march    tomi kilgore tesaro stock halted for news pending  pm march    tomi kilgore tesaro stock price target raised to  from  at fbr  co  am feb    tomi kilgore tesaro downgraded to market perform from outperform at fbr  co  am feb    tomi kilgore tesaro downgraded to market perform at leerink  am feb    caitlin huston we’re in the year of the biotech buyout and here are five prime targets  pm jan    michael brush tesaro stock price target raised to  from  at leerink partners  am jan    tomi kilgore loading more headlines newsnonmarketwatchcompanyustsro other news on tsro juno therapeutics juno q earnings surprise in store  pm july    zackscom how astrazeneca failed not once — but twice — in cancer drugs  pm july    investors business daily tesaro outlicenses niraparib to takeda for up to m  am july    seeking alpha whats in store for agios pharma agio in q earnings  am july    zackscom whats in store for conatus cnat this earnings season  am july    zackscom biotech bonanza the next leg up  pm july    seeking alpha tesaros stock dip is nothing to be afraid of  pm july    seeking alpha fdas flashing green light boosts novel drug approvals  pm july    seeking alpha  assets with negative performances  pm july    gurufocuscom could q surprise spike this beleaguered biotechs stock  pm july    investors business daily gilead could acquire this biotech — but vertex is still better analyst  pm july    investors business daily clovis clvs focuses on rubraca launch and label expansion  pm july    zackscom why national beverage tesaro and community health systems slumped today  pm july    motley fool tesaro inc tsro shares fall as company struggles to find buyer  pm july    investorplacecom tesaro down  on diminished prospects for deal  am july    seeking alpha tesaro shows good potential with major approvals this year  pm july    seeking alpha is the options market predicting a spike in tesaro inc tsro stock  am july    zackscom are gileads fortunes about to change — without an acquisition  pm july    investors business daily gilead and vertex should join — but dont hold your breath analyst  pm june    investors business daily opko health poised for growth  am june    seeking alpha loading more headlines at a glance tesaro inc  winter street suite  waltham massachusetts  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue m net income m  sales growth  employees  annual report for tsro newspressreleasecompanyustsro press releases on tsro tesaro and takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in japan  am july    globenewswire tesaro and takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in japan  am july    globe newswire tesaro to announce secondquarter  financial results on august    pm july    globenewswire sta signs supply agreement with tesaro  pm july    pr newswire  prf stocks under scanner in the biotech space  achillion pharma kite pharma acorda therapeutics and tesaro  am july    pr newswire  prf tesaro joins ocrfa as presenting sponsor of the  ovarian cancer national conference  am june    globenewswire tesaro announces lonnie moulder and mary lynne hedley named ey entrepreneurs of the yearr new england  am june    globenewswire tesaro joins healthcare businesswomens association as corporate partner  pm june    globenewswire todays research reports on stocks to watch gilead sciences and tesaro  am june    accesswire tesaro announces participation at goldman sachs th annual global healthcare conference  pm june    globenewswire corporate news blog  puma biotech announced positive results from pb phaseii data at the asco   am june    accesswire tesaro provides business and pipeline update at asco investor briefing  pm june    globenewswire tesaro announces presentations of abstracts at the  american society of clinical oncology asco annual meeting  pm may    globenewswire national survey shows resource emotional and support needs of the ovarian cancer community  am may    globenewswire tesaro partners with clinigen to initiate european managed access program for niraparib in patients with recurrent ovarian cancer  am may    globenewswire tesaro announces firstquarter  operating results  pm may    globenewswire investor network tesaro inc to host earnings call  am may    accesswire tesaro announces submission of investigational new drug application for antilag antibody tsr to the us fda  am may    globenewswire tesaro initiates registrational development program for antipd antibody tsr  am april    globenewswire tesaro announces approval of varubyr oral rolapitant tablets by european commission  am april    globe newswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwall street isn’t ready for a point tumble in the dow industrials pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages phere’s one trump fan who might make you some money pwhy it might be time to invest in the companies amazon is destroying loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  tesaro inc tesaro careers   together we can make a difference careers we are doing what matters every day for people living with cancer teamwork dedication speedit is great to be part of a highly focused organization that is driven to develop lifesaving medicines for cancer patients we are a team that enjoys learning from each other and striving to find new ways to get high quality therapies to patients as fast as possible keith wilcoxen head of strategic partnerships rd careerswho we arecurrent opportunitiesbenefitsequal opportunity tesaro inc varubi® rolapitant   together we can make a difference products full us prescribing information visit wwwvarubirxcom request medical information together with tesaro™ patient resource program productsvarubi® rolapitantzejula™ niraparib tesaro inc pipeline   together we can make a difference pipeline our development portfolio includes novel oncology and supportive care product candidates discovery preclinical phase  phase  phase  registration compound indication phase rolapitant iv cinv registration niraparib ovarian cancer maintenance nova registration niraparib ovarian cancer maintenance prima phase  niraparib ovarian cancer treatment quadra phase  niraparib  pembrolizumab triple negative breast or ovarian cancer topacio phase  niraparib  bevacizumab ovarian cancer avanova phase  niraparib  chemotherapy ewings sarcoma phase  tsr antipd mab various tumor types phase  tsr antitim mab various tumor types phase  tsr antilag mab various tumor types preclinical antilagpd antibody various tumor types discovery undisclosed small molecule io candidates various tumor types discovery  in collaboration with engot the european network for gynaecological oncological trial groups in collaboration with sarc the sarcoma alliance for research through collaborationupon successful development and regulatory approval of any of our product candidates we intend to make them available to cancer patients in north america europe and china through our own commercialization efforts and to establish a network of licensees and distributors in other geographic areas pipelinerolapitant ivniraparibimmunooncology portfolio clinical trials the links below will provide you with information regarding tesaros ongoing clinical trials a study of niraparib maintenance treatment in patients with advanced ovarian cancer following response on frontline platinumbased chemotherapy primanct a study of niraparib in patients with ovarian cancer who have received three or four previous chemotherapy regimens quadranct niraparib andor niraparibbevacizumab combination against bevacizumab alone in platinumsensitive ovarian cancer avanovanct a study of niraparib in combination with pembrolizumab mk in patients with triplenegative breast cancer or ovarian cancer topacionct a phase  dose escalation and cohort expansion study of tsr an antipd monoclonal antibody in patients with advanced solid tumors garnetnct a phase  study of tsr an antitim monoclonal antibody in patients with advanced solid tumors ambernct for medical informationrequests onlyclick here to request medical information tesaro inc  investor relations   together we can make a difference investor relations we are committed to serving the best interests of our shareholders print email share facebook google linkedin twitter email rss stock quote tsro      pm et on  previous close  open  volume  exchange nasdaq day high  day low  week high  week low   mo  mo  yr press releases  tesaro and takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in japan  tesaro to announce secondquarter  financial results on august   view all press releases investors press releases events  presentations corporate governance sec filings stock information faq investor contact press kit shareholder tools briefcase email alerts snapshot rss facebook google linkedin twitter email rss search investor relations tesaro inc about us   together we can make a difference mission tesaros dedicated and passionate associates are committed to identifying better cancer therapies who we are tesaro is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer we see new possibilities to responsibly develop and commercialize innovative treatments where others may not relationships are vital to the success of our business and we are committed to being a trusted partner to the cancer community about ushistorysenior leadershipboard of directorscontact us tesaro inc tesaro inc  page not found   together we can make a difference page not found  error page not found tesaro inc home   living with cancera caregiver of someone living with cancerlooking to enroll in a clinical triala healthcare professionala potential corporate partneran investora reporterinterested in joining the tesaro team together we can make a difference now available in the usinvestors  media click here for our press release who we are a dedicated team of professionals who we are tesaro is an oncologyfocused biopharmaceutical company learn about tesaro tesaro is dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products learn more our strategy executing on our vision our strategy our pipeline is sourced through business development and licensing learn about our strategy the tesaro team has a track record of success in identifying acquiring developing and commercializing oncology therapeutics and supportive care products that make a meaningful difference in the lives of patients learn more our pipeline developing new therapies our pipeline our product portfolio currently consists of multiple promising oncologyrelated product candidates learn about our pipeline rolapitant iv is currently being evaluated for bioequivalence to oral rolapitant niraparib is an orally active and potent poly adpribose polymerase or parp inhibitor currently being studied for the treatment of ovarian and breast cancers tsr is a potent orally available alk anaplastic lymphoma kinase inhibitor with potential applications in a variety of oncology indications learn more latest news july   tesaro and takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in japan july   tesaro to announce secondquarter  financial results on august   june   tesaro joins ocrfa as presenting sponsor of the  ovarian cancer national conference june   tesaro announces lonnie moulder and mary lynne hedley named ey entrepreneurs of the year® new england resources we have compiled a number of online resources with current information about cancer research education clinical trials and support groups that may be useful to patients and their caregivers ovarian cancerbreast cancerbrcapositive cancerslung cancerclinical trialsmedical information culture  careers tesaro is seeking passionate collaborative professionals to join our team our culture supports innovative thinking the pursuit of excellence and the sharing of ideas refer to our careers section for a complete list of opportunities microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft tesaro inc  press releases   together we can make a difference press releases we are committed to serving the best interests of our shareholders print email share facebook google linkedin twitter email rss filter releases year all years         sort by date descending date ascending update   press releases date title and summary view  tesaro and takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in japan — takedas rights include all potential indications for niraparib in japan and rights excluding prostate cancer in south korea taiwan russia and australia — tesaro to receive  html pdf add to briefcase file is in briefcase  tesaro to announce secondquarter  financial results on august   waltham mass july   globe newswire  tesaro inc nasdaqtsro will announce its secondquarter  financial results on tuesday august   after the close of the us financial markets tesaros senior management team will host a conference call and live audio webcast at  pm et on august   to discuss the com html pdf add to briefcase file is in briefcase  tesaro joins ocrfa as presenting sponsor of the  ovarian cancer national conference waltham mass june   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company is proud to support the ovarian cancer research fund alliance ocrfa as the presenting sponsor of the  ovarian cancer national conference being held july  in chicago il the ocrfa national con html pdf add to briefcase file is in briefcase  tesaro announces lonnie moulder and mary lynne hedley named ey entrepreneurs of the year® new england waltham mass june   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company is proud to announce lonnie moulder ceo and mary lynne hedley phd president and coo have been named ey entrepreneurs of the year® in life sciences development for the new england program the awa html pdf add to briefcase file is in briefcase  tesaro joins healthcare businesswomens association as corporate partner waltham mass june   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company is proud to support the healthcare businesswomens association hba as a corporate partner hba is the leading global organization committed to furthering the advancement and impact of women in healthc html pdf add to briefcase file is in briefcase  tesaro announces participation at goldman sachs th annual global healthcare conference waltham mass june   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced its participation at the goldman sachs th annual global healthcare conference to be held june   at the terranea resort in rancho palos verdes california tim pearson  html pdf add to briefcase file is in briefcase  tesaro provides business and pipeline update at asco investor briefing initial topacio data for niraparib plus keytruda® is indicative of potentially synergistic antitumor activity in platinumresistant ovarian cancerphase  results for tsr show antipd activitythree posters presented during asco describe additional an html pdf add to briefcase file is in briefcase  tesaro announces presentations of abstracts at the  american society of clinical oncology asco annual meeting investor briefing to be webcast from chicago on june   at  pm ct waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the presentation of three zejula™ niraparib abstracts at html pdf add to briefcase file is in briefcase  national survey shows resource emotional and support needs of the ovarian cancer community waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the results of the  html pdf add to briefcase file is in briefcase  tesaro partners with clinigen to initiate european managed access program for niraparib in patients with recurrent ovarian cancer waltham mass may   globe newswire  tesaro inc nasdaqtsro and clinigen group plcs aimclin clinigen idis managed access division have partnered to launch a managed access program also known as an early access program in europe for the investigational parp  inhibitor niraparib for patients with r html pdf add to briefcase file is in briefcase  tesaro announces firstquarter  operating results zejula™ approved by us fda for the maintenance treatment of women with recurrent ovarian cancer regardless of brca or biomarker status commercial launch underwayzejula added to the nccn clinical practice guidelines in oncology expanded development program for niraparib  html pdf add to briefcase file is in briefcase  tesaro announces submission of investigational new drug application for antilag antibody tsr to the us fda waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the submission of an investigational new drug ind application for tsr to the us food and drug administration tsr is a monoclonal antibody targeting lagthe ind  html pdf add to briefcase file is in briefcase  tesaro initiates registrational development program for antipd antibody tsr tsr is the first tesaro immunooncology candidate to enter a registration programongoing clinical trial expanded to enroll patients with endometrial cancerpatientcentric administration schedule with every  week dosing html pdf add to briefcase file is in briefcase  tesaro announces approval of varuby® oral rolapitant tablets by european commission varuby provides protection for delayed chemotherapyinduced nausea and vomiting cinv with a single dose as part of an antiemetic regimenup to  of patients undergoing highly or moderately emetogenic chemotherapy experience delayed cinv even when prescribed a ht receptor antagonist  html pdf add to briefcase file is in briefcase  tesaro announces participation in two investor conferences waltham mass april   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced its participation in two upcoming investor conferences the two conferences arethe leerink boston biopharma bus tour on wednesday may   html pdf add to briefcase file is in briefcase  tesaro to announce firstquarter  financial results on may   waltham mass april   globe newswire  tesaro inc nasdaqtsro will announce its firstquarter  financial results on tuesday may   after the close of the us financial markets tesaros senior management team will host a conference call and live audio webcast at  pm et on may   to discuss the companys html pdf add to briefcase file is in briefcase  tesaro announces availability of zejula™ niraparib for patients with recurrent ovarian cancer in the us zejula is the first and only parp inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancerzejula is the only parp inhibitor that has demonstrated a clinically meaningful increase in pfs regardless of brca mutation or biomarker status html pdf add to briefcase file is in briefcase  tesaro wins awards for clinical development team of the year and clinical partnership of the year waltham mass april   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company has been recognized with two clinical and research excellence care awards pharmabiotech product development team of the year was awarded to the niraparib development team and the company also rece html pdf add to briefcase file is in briefcase  tesaro announces us fda approval of zejula™ niraparib for women with recurrent ovarian cancer tesaro inc today announced that the us food and drug administration fda has approved zejula™ niraparib an oral oncedaily polyadpribose polymerase parp inhibitor for the maintenance treatment of women with recurrent epithelial ovarian fallopian tube or primary peritoneal cancer who are in a complete or partial response cr or pr to platinumbased chemotherapy pdf add to briefcase file is in briefcase  tesaro announces expanded development program for niraparib focused on the treatment of frontline metastatic ovarian and lung cancers and metastatic breast cancer expanded niraparib ovarian cancer program intended to potentially transform the treatment of frontline ovarian cancernew breast cancer clinical program for niraparib to address greatest area of unmet need and broader patient populationbravo trial no longer expected t html pdf add to briefcase file is in briefcase  tesaro announces presentation of niraparib phase  engotovnova trial secondary endpoint results during sgo national harbor md march   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the presentation of secondary endpoint results from the phase  engotovnova trial of niraparib at the  society for gynecologic oncology sgo annual meeting on womens can html pdf add to briefcase file is in briefcase  tesaro announces niraparib data presentations at the  sgo annual meeting on womens cancer waltham mass march   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced two niraparib presentations at the  society for gynecologic oncology sgo annual meeting on womens cancer march  to   in national harbor maryland  html pdf add to briefcase file is in briefcase  tesaro announces fourthquarter  operating results niraparib nda under review by fda prelaunch preparations for planned commercial launch well underwayexpanded access program eap for niraparib open in us european eap expected to open h positive opinion rendered for varuby® by the european m html pdf add to briefcase file is in briefcase  tesaro receives positive chmp opinion for varuby® waltham mass feb   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that the european medicines agencys ema committee for medicinal products for human use chmp has rendered a positive opinion for the companys marketing authorization application maa for varuby html pdf add to briefcase file is in briefcase  tesaro announces participation at two investor conferences waltham mass feb   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced its participation in two upcoming investor conferences the two conferences are the raymond james th annual institutional investors conference at the jw ma html pdf add to briefcase file is in briefcase  tesaro to announce fourthquarter  financial results on february   waltham mass feb   globe newswire  tesaro inc nasdaqtsro will announce its fourthquarter  financial results on tuesday february   after the close of the us financial markets tesaros senior management will host a conference call and live audio webcast at  pm et on february   t html pdf add to briefcase file is in briefcase  tesaro announces participation at two investor conferences waltham mass feb   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced its participation in two upcoming investor conferences the two conferences are the th annual leerink partners global healthcare conference  html pdf add to briefcase file is in briefcase  tesaro announces opening of niraparib expanded access program for us patients with ovarian cancer waltham mass jan   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the opening of an expanded access program eap in the united states for the investigational parp inhibitor niraparib through this program niraparib is being made available for eligib html pdf add to briefcase file is in briefcase  tesaro receives complete response letter for rolapitant iv from us fda no concerns raised by fda related to the rolapitant iv efficacy or safety profile and additional clinical studies are not requiredinvestor conference call and webcast scheduled for tomorrow at am et waltham mass jan   globe newswire   html pdf add to briefcase file is in briefcase  tesaro announces priority review designation for niraparib nda niraparib new drug application accepted for review by fda with a pdufa goal date of june  niraparib expanded access program eap expected to open in us in january  waltham mass dec   globe newswire  tesaro inc nasdaqtsro html pdf add to briefcase file is in briefcase  tesaro announces participation in three investor conferences waltham mass nov   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced its participation in three upcoming investor conferences the three conferences are the leerink polarxpress bus tour at the convene conference html pdf add to briefcase file is in briefcase  tesaro announces pricing of public offering of common stock waltham mass nov   globe newswire  tesaro inc nasdaqtsro announced today that it has priced an underwritten public offering of an aggregate of  shares of its common stock at an offering price to the public of  per share the gross proceeds from the offering will be approximately  mill html pdf add to briefcase file is in briefcase  tesaro announces proposed public offering of common stock waltham mass nov   globe newswire  tesaro inc nasdaqtsro announced today that it has commenced an underwritten public offering of  shares of its common stock in connection with this offering tesaro plans to grant the underwriters an option to purchase up to an additional  shares of its common stock citi html pdf add to briefcase file is in briefcase  tesaro announces thirdquarter  operating results niraparib rolling nda submission to fda complete maa accepted for review by emaprelaunch planning ongoing to support four potential product launches in  across us and europepositive phase  nova trial results presented during presidential symposium at esmo   html pdf add to briefcase file is in briefcase  tesaro announces submission of niraparib new drug application for platinumsensitive recurrent ovarian cancer waltham mass nov   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that it has completed the niraparib rolling new drug application nda submission to the us food and drug administration fda for the maintenance treatment of patients with platinums html pdf add to briefcase file is in briefcase  tesaro announces presentation of niraparib data at the  igcs biennial meeting waltham mass oct   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the presentation of data from the engotovnova trial of niraparib at the  international gynecologic cancer society igcs biennial meeting in lisbon portugal these data were pre html pdf add to briefcase file is in briefcase  tesaro announces acceptance for review of niraparib marketing authorization application by ema waltham mass oct   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that the marketing authorisation application maa for niraparib has been submitted to and accepted for review by the european medicines agency ema for the maintenance treatment of pat html pdf add to briefcase file is in briefcase  tesaro announces participation in three investor conferences waltham mass oct   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced its participation in three upcoming investor conferences the three conferences are  the credit suisse th annual healthcare conference at the phoenician in scotts html pdf add to briefcase file is in briefcase  tesaro to announce thirdquarter  financial results on november   waltham mass oct   globe newswire  tesaro inc nasdaqtsro will announce its thirdquarter  financial results on thursday november   after the close of the us financial markets tesaros senior management will host a conference call and live audio webcast at  pm et on november   to discuss the comp html pdf add to briefcase file is in briefcase  tesaro and engot announce presentation of successful niraparib phase  engotovnova trial results during esmo  simultaneous presentation of data at esmo and publication online in the new england journal of medicinetesaro investor webcast to be held at  pm cet   pm edt copenhagen oct   globe newswire  tesaro inc nasdaqtsr html pdf add to briefcase file is in briefcase  tesaro and zai lab announce collaboration development and license agreement collaboration enables the clinical development of niraparib in china by zai lab tesaro retains right to comarket in china and receives option to license up to two novel immunooncology programs outside chinawaltham mass and shanghai china sept   html pdf add to briefcase file is in briefcase  tesaro receives fda fast track designation for niraparib and initiates rolling nda submission waltham mass sept   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that the us food and drug administration fda has granted fast track designation to niraparib for the treatment of patients with recurrent platinumsensitive ovarian fallopian tube or primary peri html pdf add to briefcase file is in briefcase  tesaro announces six data presentations at the  european society for medical oncology esmo annual meeting phase  results from engotovnova trial of niraparib accepted for oral presentation during presidential symposium and inclusion in esmo press programmetesaro to webcast investor and analyst briefing on saturday october waltham mass sept   glo html pdf add to briefcase file is in briefcase  tesaro announces participation at four investor conferences waltham mass aug   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced its participation in four upcoming investor conferences the four conferences arethe wells fargo global healthcare conference at the westin boston wa html pdf add to briefcase file is in briefcase  tesaro announces secondquarter  operating results positive phase  data reported by tesaro and engot from the nova trial of niraparib in a broad population of patients with platinumsensitive recurrent ovarian cancerprelaunch planning underway to support four potential product launches in  across us and europe html pdf add to briefcase file is in briefcase  tesaro to announce secondquarter  financial results on august   waltham mass july   globe newswire  tesaro inc nasdaqtsro will announce its secondquarter  financial results on thursday august   after the close of the us financial markets tesaros senior management will host a conference call and live audio webcast at  pm et on august   to discuss the company html pdf add to briefcase file is in briefcase  engot and tesaro partnership generates positive data from engotovnova phase  trial the engotovnova trial successfully achieved its primary endpoint of pfs in the germline brca mutant cohort  the engotovnova trial successfully achieved its primary endpoint of pfs in the nongermline brca mutant cohort including both the hrdpositive and overall analysis popu html pdf add to briefcase file is in briefcase  tesaro announces closing of public offering of common stock and exercise of option by underwriters waltham mass july   globe newswire  tesaro inc nasdaqtsro today announced the closing of its previously announced underwritten public offering of common stock  tesaro sold  shares of its common stock at an offering price to the public of  per share which included  shares of common stock sold pu html pdf add to briefcase file is in briefcase  tesaro announces pricing of public offering of common stock waltham mass june   globe newswire  tesaro inc nasdaqtsro announced today that it has priced an underwritten public offering of an aggregate of  shares of its common stock at an offering price to the public of  per share the gross proceeds from the offering will be approximately  million html pdf add to briefcase file is in briefcase  tesaro announces proposed public offering of common stock waltham mass june   globe newswire  tesaro inc nasdaqtsro announced today that it has commenced an underwritten public offering of  million of its common stock in connection with this offering tesaro plans to grant the underwriters an option to purchase up to an additional  million of its common stock html pdf add to briefcase file is in briefcase  tesaros niraparib significantly improved progressionfree survival for patients with ovarian cancer in both cohorts of the phase  nova trial the nova trial successfully achieved its primary endpoint of pfs in the germline brca mutant cohort   the nova trial successfully achieved its primary endpoint of pfs in the nongermline brca mutant cohort including both the hrdpositive and overall analysis populations html pdf add to briefcase file is in briefcase  tesaro announces rolapitant data presentations at the  masccisoo annual meeting on supportive care in cancer adelaide australia june   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced nine presentations of rolapitant data at the  masccisoo annual meeting on supportive care in cancer june  to   in adelaide australia delay html pdf add to briefcase file is in briefcase  tesaro provides pipeline update at asco investor briefing rolapitant iv nda accepted for review by fda pdufa date is january  sufficient pfs events reached for data analysis of both cohorts of phase  niraparib nova trial data expected in q ind for tsr antitim antibody cleared by fda phase  study to  html pdf add to briefcase file is in briefcase  tesaro congratulates dr mary lynne hedley on being named life science entrepreneur of the year by the new england venture capital association waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company is proud to congratulate cofounder president and coo dr mary lynne hedley on being named the life science entrepreneur of the year by the new england venture capital association the  nevy awards cel html pdf add to briefcase file is in briefcase  tesaro announces five abstracts to be presented at the  american society of clinical oncology asco annual meeting waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the presentation of five abstracts at the  american society of clinical oncology asco annual meeting june  to june   in chicago in addition tesaro will host an investor and analyst bri html pdf add to briefcase file is in briefcase  tesaro announces firstquarter  operating results us launch of varubi® underway new drug application nda for iv formulation of rolapitant submittedniraparib phase  nova results anticipated in q  are positioned to be the first data from a randomized prospective phase  trial of a parp inhibitornda and html pdf add to briefcase file is in briefcase  tesaro celebrates oncology nurses with premiere of heroic hearts documentary at oncology nursing society ons st annual congress and launches just be campaign pdf add to briefcase file is in briefcase  tesaro announces submission of investigational new drug application for antitim antibody tsr to the us fda waltham mass april   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the submission of an investigational new drug ind application for tsr to the us food and drug administration tsr is a monoclonal antibody drug candidate targeting tim  html pdf add to briefcase file is in briefcase  tesaro to announce first quarter  financial results on may   waltham mass april   globe newswire  tesaro inc nasdaqtsro will announce its first quarter  financial results on thursday may   after the close of the us financial markets tesaros senior management will host a conference call and live audio webcast at  pm et on may   to discuss the companys o html pdf add to briefcase file is in briefcase  tesaro announces global prostate cancer collaboration and licensing agreement with janssen janssen to develop and commercialize niraparib for patients with prostate cancer worldwide except in japantesaro to receive up to  million in upfront and milestone payments plus royaltiesjanssen to fund all development and commercialization related to niraparib  html pdf add to briefcase file is in briefcase  tesaro announces appointment of dr kavita patel to board of directors waltham mass april   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the appointment of kavita patel md ms facp to the companys board of directors dr patel has served as a senior fellow at the brookings institution as well as a practicing physician at joh html pdf add to briefcase file is in briefcase  tesaro and md anderson cancer center announce immunooncology collaboration and exclusive license agreement goal to identify novel small molecule therapeutics against undisclosed immunooncology targets partnership complements tesaros existing immunooncology pipeline goal to identify first clinical candidate in early  ﻿waltham mass  html pdf add to briefcase file is in briefcase  tesaro announces enrollment of first patient in phase  clinical trial of tsr waltham mass march   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced it has dosed the first patient in a phase  doseescalation study of its lead antipd monoclonal antibody candidate tsr following identification of a dose and schedule for tsr the trial i html pdf add to briefcase file is in briefcase  tesaro announces validation of marketing authorisation application for oral rolapitant by the european medicines agency waltham mass march   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that the marketing authorisation application maa for oral rolapitant has been submitted to and validated by the european medicines agency rolapitant is a substance pneurokinin nk html pdf add to briefcase file is in briefcase  tesaro announces closing of  million private placement waltham mass march   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company announced today it has completed its previously announced private placement of  million shares of common stock at a price of  per share this transaction resulted in total gross proceeds to th html pdf add to briefcase file is in briefcase  tesaro submits new drug application for intravenous rolapitant to the us food and drug administration waltham mass march   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that it has submitted the new drug application nda for an intravenous iv formulation of rolapitant to the us food and drug administration fda rola html pdf add to briefcase file is in briefcase  tesaro announces fourthquarter  operating results us commercial launch of varubi® oral rolapitant well underwayniraparib phase  nova results expected in q  are positioned to be the first data from a randomized prospective phase  trial of a parp inhibitornew drug application nda submission for nirap html pdf add to briefcase file is in briefcase  tesaro announces definitive agreement for  million private placement waltham mass feb   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that it has entered into definitive agreements with institutional investors to sell  million shares of its common stock at  per share in a private placement resulting in proceeds of html pdf add to briefcase file is in briefcase  tesaro to announce fourth quarter  financial results on february   waltham mass feb   globe newswire  tesaro inc nasdaqtsro will announce its fourth quarter  financial results on thursday february   after the close of the us financial markets tesaros senior management will host a conference call and live audio webcast at  pm et on february   to  html pdf add to briefcase file is in briefcase  tesaro to present at the leerink partners th annual global healthcare conference waltham mass feb   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder ceo of tesaro and mary lynne hedley president and coo of tesaro will present at the leerink partners th annual global healthcare conference at the waldorf astoria in new york city on february   at  pm ea html pdf add to briefcase file is in briefcase  tesaro outlines business priorities and strategic outlook for  us commercial launch of varubi™ oral rolapitant well underwaydata from niraparib nova and quadra registration trials expected in q  niraparib new drug application nda submission planned for h investigational new drug in html pdf add to briefcase file is in briefcase  tesaro added to the nasdaq biotechnology index waltham mass dec   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that the company has been selected for addition to the nasdaq biotechnology index nasdaqnbi effective upon market open on december   the nasdaq biotechnology index is designed to track the html pdf add to briefcase file is in briefcase  tesaro announces the launch of varubitm rolapitant in the united states varubi™rolapitant provides extended protection for chemotherapyinduced nausea and vomiting cinv in the delayed phase  hours with a single dose as part of an antiemetic regimen more than half of patients undergoing emetogenic chemotherapy may experience delayed cinv even when prescribed a ht receptor antagonist and a cort html pdf add to briefcase file is in briefcase  tesaro announces data presentations for niraparib at the  aacrncieortc international conference on molecular targets and cancer therapeutics waltham mass nov   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the presentation of three posters describing niraparib at the  aacrncieortc international conference on molecular targets and cancer therapeutics november   in boston massachusetts the posters html pdf add to briefcase file is in briefcase  tesaro announces thirdquarter  operating results varubi™ oral rolapitant approved by us fda commercial launch planned for midnovember varubi™ added to national comprehensive cancer network nccn antiemesis guidelines with a category  level of evidence and consensus patient treatment continues in the phase  nova trial of niraparib based upon the observed event rate topline  html pdf add to briefcase file is in briefcase  tesaro announces participation in three investor conferences waltham mass oct   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced its participation in three upcoming investor conferences the three conferences arethe  citi global healthcare conference at the new york palace in new york city on wednesday november  and thursday nov html pdf add to briefcase file is in briefcase  tesaro to announce thirdquarter financial results on october   waltham mass oct   globe newswire  tesaro inc nasdaqtsro will announce its thirdquarter  financial results on thursday october   after the close of the us financial markets tesaros senior management team will host a conference call and live audio webcast at  pm et on october   to provide a business html pdf add to briefcase file is in briefcase  tesaro announces inclusion of varubitm rolapitant in nccnr antiemesis guidelines waltham mass sept   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the decision of the national comprehensive cancer network nccn to include varubi™ rolapitant in the nccn clinical practice guidelines in oncology nccn guidelines® antiemesis version  a html pdf add to briefcase file is in briefcase  tesaro appoints martin huber md as senior vice president and chief medical officer waltham mass sept   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the appointment of martin huber md to the position of senior vice president and chief medical officer dr huber will report to mary lynne hedley phd president and coo of tesaro and will lead the glo html pdf add to briefcase file is in briefcase  tesaro announces us fda approval of varubitm rolapitant for nausea and vomiting associated with cancer chemotherapy approval based upon four trials of patients receiving emetogenic chemotherapy including cisplatin carboplatin and anthracyclinecyclophosphamidebased regimens   varubi™ to address a potential us market opportunity that exceeds  billion   us commercial launch planned for q  waltham mass sept   g html pdf add to briefcase file is in briefcase  tesaro announces participation at three investor conferences waltham mass sept   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced its participation in three upcoming investor conferences the three conferences arethe th annual citi biotech day at the mandarin oriental hotel in new york city on wednesday september  and thursday sept html pdf add to briefcase file is in briefcase  tesaro announces secondquarter  operating results us fda pdufa action date for oral rolapitant is september  bioequivalence of iv and oral rolapitant successfully demonstrateddata from phase  nova trial of niraparib anticipated in q cash and cash equivalents totaled  million as of june   waltham mass aug   globe newswire  tesaro inc nasdaqtsro an on html pdf add to briefcase file is in briefcase  tesaro and jiangsu hengrui medicine announce rolapitant license agreement for china waltham mass july   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company and jiangsu hengrui medicine co ltd a fully integrated pharmaceutical company based in china today announced an exclusive license agreement for the development registration manufacture and commercialization of rolapit html pdf add to briefcase file is in briefcase  tesaro to announce secondquarter financial results on august   waltham mass july   globe newswire  tesaro inc nasdaqtsro will announce its secondquarter  financial results on thursday august   after the close of the us financial markets tesaros senior management team will host a conference call and live audio webcast at  pm et on august   to provide a business an html pdf add to briefcase file is in briefcase  tesaro appoints grant c bogle as senior vice president and chief commercial officer waltham mass july   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the appointment of grant c bogle to the newly created position of senior vice president and chief commercial officer in this role mr bogle will report to lonnie moulder ceo of tesaro and will lead tesaro html pdf add to briefcase file is in briefcase  tesaro appoints jeffrey h hanke phd as executive vice president research  development and chief scientific officer waltham mass june   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the appointment of jeffrey h hanke phd to the newly created role of executive vice president research and development and chief scientific officer in this position dr hanke will report to mary lynne  html pdf add to briefcase file is in briefcase  tesaro announces six abstracts to be presented at the  multinational association of supportive care in cancer annual meeting waltham mass june   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the presentation of six abstracts at the  multinational association of supportive care in cancer masccisoo annual meeting june  to   in copenhagenpresentation detailsefficacy and safety of  html pdf add to briefcase file is in briefcase  tesaro announces successful completion of rolapitant bioequivalence study waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the successful completion of the rolapitant bioequivalence study the results of this study indicate that the exposure for a  milligram dose of intravenous rolapitant is similar to the exposure of a  html pdf add to briefcase file is in briefcase  tesaro and merck to collaborate on a combination study of niraparib and keytrudar pembrolizumab waltham mass and kenilworth nj may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company and merck nysemrk known as msd outside the united states and canada today announced a collaboration to evaluate the combination of tesaros niraparib plus mercks antipd therapy keytruda® pem html pdf add to briefcase file is in briefcase  tesaro announces webcast of presentation at the jefferies  global healthcare conference waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company announced today that lonnie moulder ceo of tesaro will present an overview of tesaros business and development programs at the jefferies  global healthcare conference at the grand hyatt hotel in new york city on wednesd html pdf add to briefcase file is in briefcase  tesaro announces election of garry a nicholson to board of directors and results of annual stockholder meeting waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the results of its annual stockholder meeting which was held today at  am eastern time in waltham massachusetts garry a nicholson has been elected to the tesaro board of directors in addition to electi html pdf add to briefcase file is in briefcase  tesaro announces seven abstracts to be presented at the  american society of clinical oncology asco annual meeting waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the presentation of seven abstracts at the  american society of clinical oncology asco annual meeting may  to june   in chicago in addition tesaro will host an investor and analyst briefing in html pdf add to briefcase file is in briefcase  tesaro announces completion of targeted enrollment in phase  nova trial and initiation of the quadra trial of niraparib both the nongermline and germline brca mutation cohorts within nova are fully enrolled phase  data from nova is expected in q  patients are now being treated within the quadra trial waltham mass april   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today provided an upd html pdf add to briefcase file is in briefcase  tesaro announces firstquarter  operating results target enrollment completed for both cohorts of the niraparib phase  nova trial data expected in q quadra trial of niraparib initiated initial data anticipated in early us fda pdufa action date for oral rolapitant is september  cash and cash equivalents totaled approximately  million as of march   waltham mass html pdf add to briefcase file is in briefcase  tesaro launches campaign to raise awareness of chemotherapyinduced nausea and vomiting among patients with cancer waltham mass april   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the launch of ask about cinv a campaign to raise awareness of chemotherapyinduced nausea and vomiting cinv and the importance of fostering an open dialogue about cinv among patients and their health care  html pdf add to briefcase file is in briefcase  tesaro announces participation at three investor conferences waltham mass april   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced its participation in three investor conferences during the month of may including the mizuho securities usa third annual healthcare corporate access day in new york city on tuesday may   t html pdf add to briefcase file is in briefcase  tesaro to announce firstquarter financial results on april   waltham mass april   globe newswire  tesaro inc nasdaqtsro will announce its firstquarter  financial results on thursday april   after the close of the us financial markets tesaros senior management team will host a conference call and live audio webcast at  pm et on april   to provide a business an html pdf add to briefcase file is in briefcase  tesaro announces upcoming immunooncology presentations waltham mass april   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced two upcoming presentations related to its immunooncology portfolio the company will participate in the jefferies  immunooncology summit at the boston harbor hotel on april   mary lynne hed html pdf add to briefcase file is in briefcase  tesaro announces nomination of garry a nicholson for election to board of directors waltham mass april   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the nomination of garry a nicholson for election to the companys board of directors he will stand for election as an independent director at tesaros  annual meeting of stockholders which is scheduled  html pdf add to briefcase file is in briefcase  tesaro appoints joseph farmer as senior vice president general counsel and secretary waltham mass march   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the appointment of joseph l farmer as senior vice president general counsel and secretary mr farmer most recently served as vice president chief corporate counsel and assistant secretary of cubist pharma html pdf add to briefcase file is in briefcase  tesaro announces closing of public offering of common stock and exercise of overallotment option by underwriters waltham mass march   globe newswire  tesaro inc nasdaqtsro today announced the closing of its previously announced underwritten public offering of common stock tesaro sold  shares of common stock at an offering price to the public of  per share which included  shares of common stock sold pursuant to the par html pdf add to briefcase file is in briefcase  tesaro to present at the barclays global healthcare conference waltham mass march   globe newswire  tesaro inc nasdaqtsro announced today that mary lynne hedley phd president and coo of tesaro will present at the barclays global healthcare conference at the loews hotel in miami on march   at  pm eastern time a live webcast of this presentation will be accessible via the inves html pdf add to briefcase file is in briefcase  tesaro announces pricing of public offering of common stock waltham mass march   globe newswire  tesaro inc nasdaqtsro announced today that it has priced an underwritten public offering of an aggregate of  shares of its common stock at a price to the public of  per share the gross proceeds from the offering will be approximately  million in addition tesaro has grant html pdf add to briefcase file is in briefcase  tesaro announces proposed public offering of common stock waltham mass march   globe newswire  tesaro inc nasdaqtsro announced today that it has commenced an underwritten public offering of  million of its common stock in connection with this offering tesaro plans to grant the underwriters an option to purchase up to an additional  million of its common stock to cover overall html pdf add to briefcase file is in briefcase  tesaro announces fourthquarter  operating results enrollment in niraparib nova nongbrca cohort on track to complete during q  new quadra trial of niraparib for the treatment of ovarian cancer to begin in q us fda pdufa action date for oral rolapitant is september  cash and cash equivalents totaled approximately  million as of december   waltham mass feb   html pdf add to briefcase file is in briefcase  tesaro to present at the leerink global healthcare conference waltham mass feb   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder ceo of tesaro will present at the leerink global healthcare conference at the waldorf astoria in new york city on february   at  am eastern time a live webcast of this presentation will be accessible via the investors page  html pdf add to briefcase file is in briefcase  tesaro to announce fourthquarter  financial results on february   waltham mass feb   globe newswire  tesaro inc nasdaqtsro will announce its fourthquarter  financial results on thursday february   after the close of the us financial markets tesaros senior management team will host a conference call and live audio webcast at  pm et on february   to discuss the comp html pdf add to briefcase file is in briefcase  tesaro announces expansion of niraparib clinical program and outlines latestage program milestones for   new trial of niraparib for the treatment of ovarian cancer to begin in q   hrd assay to be incorporated into phase  nova trial of niraparib in ovarian cancer   initial phase  data from nova is expected to become available in    us fda pdufa action date for oral rolapitant is september   waltham mass jan    html pdf add to briefcase file is in briefcase  tesaro and anaptysbio expand immunooncology collaboration to include novel bispecific antibody candidate candidate will target two undisclosed immune checkpointsantitim antibody data to be presented today at the aacr conference in orlando waltham mass and san diego dec   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company and anaptysbio inc a privatelyheld therapeutic antibody company html pdf add to briefcase file is in briefcase  tesaro to present at the  deutsche bank biofest waltham mass nov   globe newswire  tesaro inc nasdaqtsro announced today that mary lynne hedley phd president and coo of tesaro will present at the  deutsche bank biofest conference on tuesday december   at  pm et in boston a live webcast will be accessible via the investors page of the tesaro website at  html pdf add to briefcase file is in briefcase  tesaro to present at the nasdaq st investor program waltham mass nov   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder ceo of tesaro will present at the nasdaq st investor program on tuesday december   at  am gmt in london a live webcast will be accessible via the investors page of the tesaro website at wwwtesarobiocom an archived  html pdf add to briefcase file is in briefcase  tesaro and myriad announce companion diagnostics collaboration barcelona november    tesaro inc nasdaq tsro and myriad genetics nasdaq mygn today announced a collaboration utilizing myriads mychoice hrd companion diagnostic cdx to identify tumor tissue with a deficiency in homologous recombination under the terms of the agreement tesaro will utilize myriads test to enrich the target html pdf add to briefcase file is in briefcase  tesaro to present at the jefferies  global healthcare conference waltham mass nov   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder ceo of tesaro will present at the jefferies  global healthcare conference on wednesday november   at  am gmt in london a live webcast will be accessible via the investors page of the tesaro website at wwwtesarobio html pdf add to briefcase file is in briefcase  tesaro announces thirdquarter  operating results oral rolapitant new drug application nda accepted for review by us fdaenrollment in niraparib nova trial nongbrca cohort on track to be complete at year end antilag clinical lead antibody identified cash and cash equivalents totaled approximately  million as of september   waltham mass nov   globe newswire  tes html pdf add to briefcase file is in briefcase  tesaro to announce thirdquarter  financial results on november   waltham mass oct   globe newswire  tesaro inc nasdaqtsro will announce its thirdquarter  financial results on wednesday november   after the close of the us financial markets tesaros senior management team will host a conference call and live audio webcast at  pm et on november   to discuss the compa html pdf add to briefcase file is in briefcase  tesaro announces closing of  million public offering of  convertible senior notes due  including full exercise of the underwriters option to purchase additional notes waltham mass sept   globe newswire  tesaro inc nasdaqtsro announced today the closing of its previously announced underwritten public offering of  million aggregate principal amount of its  convertible senior notes due  the notes including the notes issued pursuant to the full exercise of the underwriters o html pdf add to briefcase file is in briefcase  tesaro announces pricing of  million of  convertible senior notes due  waltham mass sept   globe newswire  tesaro inc nasdaqtsro announced today the pricing of  million aggregate principal amount of its  convertible senior notes due  the notes in an underwritten public offering the size of the offering was increased from the previously announced aggregate principal amount of   html pdf add to briefcase file is in briefcase  tesaro announces offering of  million of convertible senior notes due  waltham mass sept   globe newswire  tesaro inc nasdaqtsro announced today that subject to market and other conditions it intends to offer  million aggregate principal amount of convertible senior notes due  the notes in an underwritten public offering tesaro also expects to grant the underwriters a day option t html pdf add to briefcase file is in briefcase  tesaro announces submission of rolapitant new drug application nda to us food and drug administration waltham mass sept   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that it has submitted the new drug application nda for oral rolapitant to the us food and drug administration fda rolapitant is an investigational neurokinin nk receptor antagonist developed for t html pdf add to briefcase file is in briefcase  tesaro announces participation at several upcoming investor conferences waltham mass aug   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company announced that lonnie moulder ceo mary lynne hedley phd president and coo and tim pearson executive vice president and cfo of tesaro will participate in several upcoming investor conferences during the month of septe html pdf add to briefcase file is in briefcase  tesaro appoints mary lynne hedley phd as chief operating officer waltham mass july   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that mary lynne hedley phd president and cofounder of tesaro has been appointed to the role of chief operating officer since the founding of tesaro in  mary lynne has been instrumental in defi html pdf add to briefcase file is in briefcase  tesaro announces secondquarter  operating results oral rolapitant new drug application nda on track for submission to us fdaenrollment in niraparib nova trial nongbrca cohort expected to be complete at year end enrollment in phase  trial of niraparib in patients with ewings sarcoma initiatedantitim clinical lead and back up antibodies identified cash and cash equivalents totaled approxim html pdf add to briefcase file is in briefcase  tesaro to announce secondquarter  financial results on july   waltham mass july   globe newswire  tesaro inc nasdaqtsro will announce its secondquarter  financial results on thursday july   after the close of the us financial markets tesaros senior management team will host a conference call and live audio webcast at  pm et on july   to discuss the companys r html pdf add to briefcase file is in briefcase  tesaro summarizes rolapitant data presented at the  masccisoo international symposium on supportive care in cancer miami june   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that three oral presentations detailing the final results from the rolapitant registration program were delivered today at the masccisoo international symposium on supportive care in cancer annual meeting in miami ro html pdf add to briefcase file is in briefcase  tesaro summarizes phase  rolapitant data presented at the  american society of clinical oncology asco annual meeting and provides an update on niraparib development strategy oral rolapitant new drug application nda submission on track for middevelopment plans for niraparib in small cell lung cancer and firstline ovarian cancer announced chicago june   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that final results from three phase  tr html pdf add to briefcase file is in briefcase  tesaro appoints tim pearson as chief financial officer waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the appointment of tim pearson as chief financial officer mr pearson was most recently executive vice president and chief financial officer of catalyst health solutions inc where he led the finance and str html pdf add to briefcase file is in briefcase  tesaro announces webcast of investor  analyst briefing at asco waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company invites investors and the general public to listen to a webcast of an investor briefing scheduled for sunday june  at  pm central time in conjunction with the  american society of clinical oncology asco annual meet html pdf add to briefcase file is in briefcase  tesaro announces election of earl m duke collier jr to board of directors and results of annual stockholder meeting waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that earl m duke collier jr has been elected to the tesaro board of directors on behalf of the company and the entire board i would like to thank paul walker for his leadership and years of service  html pdf add to briefcase file is in briefcase  tesaro announces six abstracts to be presented at the  american society of clinical oncology asco annual meeting waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced the presentation of six abstracts at the  american society of clinical oncology asco annual meeting may  to june   in chicago the presentations will include detailed results from the three phas html pdf add to briefcase file is in briefcase  tesaro to present at the ubs  global healthcare conference waltham mass may   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder ceo of tesaro and dr mary lynne hedley president of tesaro will present at the ubs  global healthcare conference on wednesday may   at  am eastern time at the sheraton new york times square hotel a live webcast html pdf add to briefcase file is in briefcase  tesaro announces successful achievement of primary and all secondary endpoints in third and final phase  trial of rolapitant achieved primary endpoint of complete response cr in the delayed period  to  hours following initiation of chemotherapyachieved key secondary endpoints of cr in the acute and overall periodsachieved all secondary endpoints including no significant nauseaadverse event profile consistent with earlier clinical trialsnew drug application nda html pdf add to briefcase file is in briefcase  tesaro to present at the deutsche bank securities th annual health care conference waltham mass may   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder ceo of tesaro and dr mary lynne hedley president of tesaro will present at the deutsche bank securities th annual health care conference on wednesday may   at  pm eastern time at the intercontinental hotel boston a li html pdf add to briefcase file is in briefcase  tesaro announces firstquarter  operating results oral rolapitant new drug application on track for submission to us fda in midmultiple data presentations planned for the  asco meeting niraparib phase  bravo and nova trials enrolling patientscash and cash equivalents totaled approximately  million as of march   waltham mass april   globe newswire  tesaro  html pdf add to briefcase file is in briefcase  tesaro to announce first quarter  financial results on april   waltham mass april   globe newswire  tesaro inc nasdaqtsro will announce its first quarter  financial results on wednesday april   after the close of the us financial markets tesaros senior management will host a conference call and live audio webcast at  pm et on april   to discuss the companys res html pdf add to briefcase file is in briefcase  tesaro announces data presentations at  aacr annual meeting waltham mass april   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that two posters highlighting its niraparib and immunooncology programs will be presented at the american association of cancer research aacr meeting which will take place april   in san diego cal html pdf add to briefcase file is in briefcase  tesaro and anaptysbio announce collaboration and exclusive worldwide license agreement for multiple immunooncology programs immunooncology platform provides a portfolio of candidates focused on high value targets potentially augments the value of other pipeline candidates and enhances prospects for future collaborations to advance tesaros overall oncology strategy potential firstinclass antitim antibody clinical candidate expected to be selected secondquarter  html pdf add to briefcase file is in briefcase  tesaro to present at the barclays global healthcare conference waltham mass march   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder ceo of tesaro will present at the barclays global healthcare conference in miami on thursday march   at  am eastern time a live webcast will be accessible via the investors page of the tesaro website at wwwtesarobioco html pdf add to briefcase file is in briefcase  tesaro announces fourthquarter and fullyear  operating results oral rolapitant new drug application on track for submission to us fda in midniraparib phase  nova and bravo trials continue to advancecash and cash equivalents totaled approximately  million as of december   successful followon offering raised approximately  million in february  waltham mass feb   globe n html pdf add to briefcase file is in briefcase  tesaro to announce fourth quarter  financial results on february   waltham mass feb   globe newswire  tesaro inc nasdaqtsro will announce its fourth quarter  financial results on wednesday february   after the close of the us financial markets tesaros senior management will host a conference call and live audio webcast at  pm et on february   to discuss the company html pdf add to briefcase file is in briefcase  tesaro to present at two upcoming investment conferences waltham mass feb   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder ceo of tesaro and mary lynne hedley phd president of tesaro will participate in two investment conferences in february including the leerink swann global healthcare conference at the waldorf astoria in new york city tesaro  html pdf add to briefcase file is in briefcase  tesaro announces pricing of public offering of common stock waltham mass jan   globe newswire  tesaro inc nasdaqtsro announced today that it has priced an underwritten public offering of an aggregate of  shares of its common stock at a price to the public of  per share the gross proceeds from the offering will be approximately  million in addition tesaro has granted html pdf add to briefcase file is in briefcase  tesaro announces proposed public offering of common stock waltham mass jan   globe newswire  tesaro inc nasdaqtsro announced today that it has commenced an underwritten public offering of  million of its common stock in connection with this offering tesaro plans to grant the underwriters an option to purchase up to an additional  million of its common stock to cover overallot html pdf add to briefcase file is in briefcase  tesaro to present at the nd annual jp morgan healthcare conference waltham mass jan   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder ceo of tesaro and mary lynne hedley phd president of tesaro will attend the nd annual jp morgan healthcare conference at the westin st francis hotel in san francisco mr moulder will make a presentation at the conference on t html pdf add to briefcase file is in briefcase  tesaro announces successful achievement of primary endpoint in each of two phase  trials of rolapitant for the prevention of chemotherapyinduced nausea  vomiting cinv a phase  trial in patients receiving moderately emetogenic chemotherapy mec met the primary endpoint of complete response in the delayed period  hours following initiation of chemotherapya phase  trial in patients receiving highly emetogenic chemotherapy hec also met the primary endpoint of complete response in the delayed period foll html pdf add to briefcase file is in briefcase  tesaro to present at the  deutsche bank biofest conference waltham mass nov   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder ceo of tesaro and mary lynne hedley phd president of tesaro will present at the  deutsche bank biofest conference at the four seasons hotel in boston on monday december   at  pm eastern time a live webcast will  html pdf add to briefcase file is in briefcase  tesaro announces thirdquarter  operating results topline results expected to be announced at yearend  from two phase  trials of oral rolapitantpatient enrollment in the third phase  trial of oral rolapitant expected to conclude at year end topline results now anticipated in early  dose ranging study of intravenous rolapitant expected to complete by year endpatient enrollment ongoing html pdf add to briefcase file is in briefcase  tesaro to announce third quarter  financial results on november   waltham mass oct   globe newswire  tesaro inc nasdaqtsro will announce its third quarter  financial results on thursday november   after the close of the us financial markets tesaros senior management will host a conference call and live audio webcast on thursday november   at  pm et to discuss the c html pdf add to briefcase file is in briefcase  tesaro announces initiation of rolapitant iv clinical program waltham mass sept   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that an open label dosefinding and escalation study has been initiated to evaluate the pharmacokinetics safety and tolerability of an intravenous iv formulation of rolapitant in healthy volunteers rolap html pdf add to briefcase file is in briefcase  tesaro describes initial phase  clinical data for tsr presented at the european cancer congress  tsr identified as a potent dual inhibitor of alk and trk kinasespreliminary clinical activity demonstrated in patients with several tumors including alkpositive nsclc patients previously treated with crizotinibphase  dose selection and cohort expansion into patients with alkpositive or trkmutated tumors anticipated to occur by year end  html pdf add to briefcase file is in briefcase  tesaro to participate in several upcoming investor conferences waltham mass aug   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company announced that lonnie moulder ceo of tesaro and mary lynne hedley phd president of tesaro will participate in several upcoming investor conferences during the month of september includingcitis th annual biotech day html pdf add to briefcase file is in briefcase  tesaro announces secondquarter  operating results topline results from rolapitant phase  program to be announced by yearend patient enrollment ongoing in phase  trial of niraparib in ovarian cancer phase  trial of niraparib in breast cancer on track to begin h first tsr clinical data accepted for presentation at esmo cash and cash equivalents totaled  million as of june   html pdf add to briefcase file is in briefcase  tesaro initiates phase  trial of niraparib for treatment of patients with ovarian cancer waltham mass july   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that it has initiated patient enrollment in a phase  trial of niraparib an inhibitor of poly adpribose polymerase parp for the treatment of ovarian cancer this trial referred to as nova will evaluate  html pdf add to briefcase file is in briefcase  tesaro to announce second quarter  financial results on july   waltham mass july   globe newswire  tesaro inc nasdaqtsro will announce its second quarter  financial results on thursday july   after the close of the us financial markets tesaros senior management will host a conference call and live audio webcast on thursday july   at  pm et to discuss the compan html pdf add to briefcase file is in briefcase  tesaro to present at the th annual jmp securities healthcare conference waltham mass july   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder chief executive officer will present at the th annual jmp securities  healthcare conference at the st regis hotel in new york city on tuesday july   at  pm edt interested parties may access a live audio webcast of t html pdf add to briefcase file is in briefcase  tesaro announces presentation of rolapitant pharmacokinetic pk data at the masccisoo international symposium pk data from drugdrug interaction study describes lack of cypa interactions berlin june   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that results from a pharmacokinetic study of rolapitant an nk receptor antagonist were presented this morning at the multinational html pdf add to briefcase file is in briefcase  tesaro details niraparib phase  clinical data presented at the  asco annual meeting a recist response rate of  was achieved at the mg dose in patients with platinumsensitive high grade serous ovarian cancer a recist response rate of  was achieved across all dose levels in patients with platinum sensitive ovarian cancer and germline brca mutations progression free survival exceeded one year among platinumsensitive ovaria html pdf add to briefcase file is in briefcase  tesaro breast international group big and the european organization for research and treatment of cancer eortc announce collaboration for niraparib clinical development in breast cancer chicago and brussels belgium june   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company breast international group big a nonprofit organization for academic breast cancer research groups from around the world and the european organization for research and treatment of cancer eortc an intern html pdf add to briefcase file is in briefcase  tesaro and the european network of gynecological oncological trial groups engot forge partnership to develop niraparib for ovarian cancer chicago june   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company and the european network of gynecological oncological trial groups engot a network of national and regional clinical trial organizations today announced a partnership for the phase  clinical development of niraparib an orally a html pdf add to briefcase file is in briefcase  tesaro to webcast investor briefing at asco waltham mass may   globe newswire  tesaro inc nasdaqtsro invites investors and the general public to listen to a webcast of a presentation by the tesaro management team at an investor briefing on sunday june   at  pm central time in connection with the annual meeting of the american society of clinical oncology asc html pdf add to briefcase file is in briefcase  tesaro to present at the deutsche bank th annual  health care conference waltham mass may   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder chief executive officer and mary lynne hedley phd president will present at the deutsche bank th annual  health care conference at the westin boston waterfront hotel on wednesday may   at  pm edt interested pa html pdf add to briefcase file is in briefcase  tesaro announces presentation of niraparib clinical data at the  asco annual meeting final phase  results demonstrate activity in ovarian and breast cancerphase  trial in ovarian cancer to begin enrolling patients by midyearphase  trial in patients with breast cancer on track to initiate in h waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today  html pdf add to briefcase file is in briefcase  tesaro announces election of dr james armitage to board of directors and results of annual stockholder meeting waltham mass may   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today announced that james o armitage md facp frcp has been elected to the tesaro board of directors this election increases the number of independent directors on the companys board to six dr armitage is html pdf add to briefcase file is in briefcase  tesaro announces firstquarter  operating results phase  trial of niraparib in breast cancer to be initiated in the second half of phase  trial of niraparib in ovarian cancer on track to begin enrolling midtopline results of rolapitant phase  program to be announced in the second half of fifth dose level achieved in phase  clinical trial of tsrnet cash position totaled appr html pdf add to briefcase file is in briefcase  tesaro to announce first quarter  financial results on april   waltham mass april   globe newswire  tesaro inc nasdaqtsro will announce its first quarter  financial results on thursday april   after the close of the us financial markets tesaros senior management will host a conference call and live audio webcast on thursday april   at  pm et to discuss the comp html pdf add to briefcase file is in briefcase  tesaro to present at the th annual future leaders in the biotech industry conference waltham mass march   globe newswire  tesaro inc nasdaqtsro announced today that mary lynne hedley phd president and chief scientific officer will present at the th annual future leaders in the biotech industry conference at the millennium broadway hotel and conference center in new york city on friday april   at  html pdf add to briefcase file is in briefcase  tesaro announces closing of public offering and full exercise of overallotment option by underwriters waltham mass march   globe newswire  tesaro inc nasdaqtsro announced today the closing of its previously announced underwritten public offering of common stock the total number of shares of common stock sold was  composed of  shares of common stock initially offered and an additional  shares of common st html pdf add to briefcase file is in briefcase  tesaro announces pricing of upsized public offering of common stock waltham mass feb   globe newswire  tesaro inc nasdaqtsro announced today that it has priced an underwritten public offering of an aggregate of  shares of its common stock at a price to the public of  per share the gross proceeds from the offering will be approximately  million upsized from the previously annou html pdf add to briefcase file is in briefcase  tesaro announces proposed public offering of common stock waltham mass feb   globe newswire  tesaro inc nasdaqtsro announced today that it has commenced an underwritten public offering of  million of its common stock in connection with this offering tesaro plans to grant the underwriters an option to purchase up to an additional  shares of its common stock to cover over html pdf add to briefcase file is in briefcase  tesaro announces fourth quarter and yearend  operating results niraparib to be advanced in a phase  pivotal trial for ovarian cancerenrollment continues in the global registration program for rolapitantachieved third doselevel in a phase  clinical trial of tsr waltham mass feb   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today reported f html pdf add to briefcase file is in briefcase  tesaro to announce fourth quarter and year end  financial results on thursday february th  waltham mass feb   globe newswire  tesaro inc nasdaqtsro will announce its fourth quarter and year end  financial results on thursday february th  before the opening of the us financial markets tesaros senior management will host a conference call and live webcast on thursday february th  at  am e html pdf add to briefcase file is in briefcase  tesaro to present at the leerink swann global healthcare conference waltham mass feb   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder chief executive officer and mary lynne hedley phd president and chief scientific officer will present at the leerink swann global healthcare conferenceat the waldorf astoria hotel in new york on thursday february   at  html pdf add to briefcase file is in briefcase  tesaro to present at the deutsche bank  dbaccess biofest waltham mass nov   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder chief executive officer and mary lynne hedley phd president and chief scientific officer will present at the deutsche bank  dbaccess biofest at the four seasons hotel in boston on monday december   at  pm edt  html pdf add to briefcase file is in briefcase  tesaro and virginia g piper cancer center announce enrollment of first patient in clinical trial of tsr waltham mass nov   globe newswire  tesaro inc nasdaqtsro announced today that the first clinical trial of its proprietary anaplastic lymphoma kinase alk inhibitor tsr has commenced with the dosing of the first patient at the virginia g piper cancer center clinical trials at scottsdale healthcare a partnership between sc html pdf add to briefcase file is in briefcase  tesaro announces third quarter  operating results continued enrollment for the global registration program for rolapitantannounced clearance of investigational new drug application for tsrappointed robert e martell md phd as chief medical officer waltham mass oct   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical company today report html pdf add to briefcase file is in briefcase  tesaro to announce third quarter  financial results on thursday october th  waltham mass oct   globe newswire  tesaro inc nasdaqtsro will announce its third quarter  financial results on thursday october th  after the close of the us financial markets tesaros senior management will host a conference call and live audio webcast on thursday october th  at  pm et to discuss  html pdf add to briefcase file is in briefcase  tesaro announces clearance of investigational new drug application for tsr waltham mass oct   globe newswire  tesaro inc nasdaqtsro announced today that the investigational new drug ind application for tsr an orally available alk inhibitor targeted anticancer agent has become effective the company plans to dose the first patient in a phase  clinical study within the next few months  f html pdf add to briefcase file is in briefcase  tesaro inc appoints robert e martell md phd as chief medical officer waltham mass sept   globe newswire  tesaro inc nasdaqtsro today announced the appointment of dr robert martell as chief medical officer dr martell is a practicing medical oncologist at tufts medical center who brings extensive drug development experience to tesaro from both industry and academia he most recently served as ass html pdf add to briefcase file is in briefcase  tesaro inc to present at the  morgan stanley global healthcare conference waltham mass sept   globe newswire  tesaro inc nasdaqtsro announced today that lonnie moulder chief executive officer and mary lynne hedley phd president and chief scientific officer will present at the  morgan stanley global healthcare conference at the grand hyatt in new york on monday september   at  pm html pdf add to briefcase file is in briefcase  tesaro inc to present at upcoming conferences waltham mass aug   globe newswire  tesaro inc nasdaqtsro today announced that lonnie moulder chief executive officer will be presenting at the robert w baird  healthcare conference at the new york palace hotel in new york on thursday september   at  pm edt also the company announced that mr moulder will be html pdf add to briefcase file is in briefcase  tesaro announces second quarter  operating results key rolapitant clinical trial results presented at asco and mascc meetingsinlicensed niraparib a potentially first and bestinclass parp inhibitorraised over  million in gross proceeds from an initial public offering waltham mass july   globe newswire  tesaro inc nasdaqtsro an oncologyfocused biopharmaceutical compa html pdf add to briefcase file is in briefcase  tesaro inc announces exercise of underwriters overallotment option waltham mass july   globe newswire  tesaro inc nasdaqtsro announced today that the underwriters of its initial public offering have partially exercised their overallotment option for the purchase of an additional  shares of tesaro common stock all of such shares were sold by tesaro at the initial public offering price of html pdf add to briefcase file is in briefcase  tesaro inc to announce second quarter  financial results on thursday july th  waltham mass july   globe newswire  tesaro inc nasdaqtsro will announce its second quarter  financial results on thursday july th  before the open of the us financial markets tesaros senior management will host a conference call and live audio webcast on thursday july th at  am et to discuss the company html pdf add to briefcase file is in briefcase  tesaro inc announces pricing of initial public offering waltham mass june   globe newswire  tesaro inc announced today the pricing of its initial public offering of  shares of its common stock at a price to the public of  per share the shares of tesaros common stock have been approved for listing on the nasdaq global select market and are expected to begin trading tomorr html pdf add to briefcase file is in briefcase  tesaro named as a  fierce  biotech company pdf add to briefcase file is in briefcase  tesaro announces  million series b financing for advancement expansion of oncology product portfolio pdf add to briefcase file is in briefcase  exclusive license agreement with amgen to acquire rights to anaplastic lymphoma kinase alk program pdf add to briefcase file is in briefcase  tesaro and opko health sign exclusive license agreement for pdf add to briefcase file is in briefcase  tesaro inc secures  million in startup funding boston ma  may    tesaro inc an oncologyfocused biopharmaceutical company today announced that it has secured  million in startup funding to acquire develop and commercialize cancer therapeutics and supportive care products participants in a  million series a financing included new enterprise associates nea an pdf add to briefcase file is in briefcase page     next last   view all items  add release to briefcase investors press releases events  presentations corporate governance sec filings stock information faq investor contact press kit shareholder tools briefcase email alerts snapshot rss facebook google linkedin twitter email rss search investor relations